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Introduction 
1. INTRODUCTION 
1.1. BENZOTHIAZOLE NUCLEUS 
A heterocyclic compound is one which possesses a cyclic structure with at least two different 
kinds of hetero atoms in the ring. Nitrogen, oxygen and sulphur are the most common 
heteroatoms. Heterocyclic compounds are very widely distributed in nature and are essential to 
life in various ways. Most of the sugars and their derivatives, including vitamin C, for instance, 
exist in the form of five-membered (furan) or six-membered (pyran) rings containing one oxygen 
atom. Most member of vitamin B group possess heterocyclic ring containing nitrogen. One 
example is vitamin B6 (pyridoxine), which is a derivative of pyridine, essential in amino acid 
metabolism. [1] 
Benzothiazole moieties are part of compounds showing numerous biological activities such as 
antimicrobial, [2-6] anticancer, [7-9, 10] anthelmintic, [11] anti-diabetic [12] activities. They have also 
found application in industry as anti-oxidants, vulkanisation accelerators. Various benzothiazoles 
such as 2-aryl benzothiazole received much attention due to unique structure and its uses as 
radioactive amyloid imagining agents,[13] and anticancer[14] agents. Benzothiazoles are bicyclic 
ring system with multiple applications. 
In the 1950s, a number of 2-nitrobenzothiazoles were intensively studied, as the 2- nitro 
benzothiazole scaffold is one of privileged structure in medicinal chemistry and reported 
cytotoxic on cancer cells [15]. It must be emphasized that combination of 2- nitrobenzothiazoles 
with other heterocyclic is a well known approach to design new drug like molecules, which 
allows achieving new pharmacological profile, action, toxicity lowering. The 2-
nitrobenzothiazoles are novel class of potent and selective antitumor agents and display 
characteristic profile of cytotoxic response across the cell lines. In addition, benzothiazole ring is 
present in various marine or terrestrial natural compounds, which have useful biological 
properties. In last few years it was reported that benzothiazole, its bioisosters and derivatives had 
antimicrobial activities against gram-negative, gram-positive bacteria and fungi. 
 
Benzothiazoles (1-thia-3-azaindene) are fused membered rings, which contain the heterocycles 
bearing thiazole. Sulphur and nitrogen atoms constitute the core structure of thiazole and many 
pharmacologically and biologically active compounds. 
 
                                                          I-1                I-2 
Thiazole is structurally related to thiophene and pyridine, but in most of its properties it 
resembles to the latter. Thiazole was first described by Hantzsch and Waber in 1887. Popp 
confirmed its structure in 1889. The basic structure of benzothiazole consist of benzene ring 
fused with 4, 5 position of thiazole. The two rings together constitute the basic nucleus 1, 3-
benzothiazole. 
1.1.1. MEDICINAL IMPORTANCE OF BENZOTHIAZOLE NUCLEUS 
A large number of therapeutic agents are synthesized with the help of Benzothiazole nucleus. 
During recent years there have been some interesting developments in the biological activities of 
benzothiazole derivatives. These compounds have special significance in the field of medicinal 
chemistry due to their remarkable pharmacological potentialities. 
1.1.2. STRUCTURAL ACTIVITY RELATIONSHIP STUDY 
Presence of hydrophobic moieties in molecule is conductive for cytotoxic activity of 
benzothiazole derivatives against cancer cell lines. The amino, hydroxyl, and chloro group 
containing benzothiazole shows better anticancer activity. [16] 
 
I-3 
The substituent’s at second position of benzothiazole ring like mercapto group and hydrazine 
group are responsible for marked bactericidal activity and anti-inflammatory activity. [17] 
 
                                 I-4                                                        I-5 
Introduction of methoxy group (-OCH3) at position 4 of 2-mercaptobenzothiazole increase 
antibacterial activity and introduction of chloro group (-Cl) at same position increase antifungal 
activity. [18] 
 
                                   I-6                                                      I-7 
Minor modification of dihydroxyphenyl group, removal of fluro group or its replacement with 
other halogens had a profoundly dyschemotherapeuitic effect with respect to in vitro cancer cell 
growth inhibitory activity. [19, 20] 
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The thiazole ring has been extensively studied and it forms a part of vitamin B, penicillins and 
the antibacterial thiazoles. Given below is a brief account of various structural modifications 
done on benzothiazole ring and their associated biological activities. 
 
1.1.3. SYNTHESIS OF BENZOTHIAZOLE 
Benzothiazoles consist of a 5-membered 1, 3-thiazole ring fused to a benzene ring. The eight 
atoms of the bicycle and the attached substituent’s are coplanar. 
1. Benzothiazole are prepared by treatment of 2-aminobenzenethiol with acid chlorides.[21] 
 
I-9 
2. Benzothiazole may be prepared by action of acid anhydrides (or) chlorides on o-amino 
phenols and formic acid in presence of acetic anhydride.[22] 
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3. Benzothiazoles are also formed by action of phosphorus pentasulfide on o-
acylaminophenoles.[23] 
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4. 2-Mercaptobenzothiazole is vulkanisation accelerator it may be prepared as follows.[24] 
 
 
I-12 
5.  Benzothiazoles prepared  from simple thioanilides and using Dess-Martin periodinane to   
promote the cyclization in 15 minutes.[25] 
 
 
I-13 
6. Preparation of 2-(Alkyl)arylbenzothiazoles from the Corresponding o-
Halobenzanilides.[26] 
 
I-14 
 
 
 
1.2. PYRAZOLONE NUCLEUS 
Pyrazolones are well known and important nitrogen containing five-membered heterocyclic 
compounds. Various methods have been worked out for their syntheses. Synthesis and 
characterization of pyrazolone derivatives has been a developing field within the realm of 
heterocyclic chemistry for the past several decades because of their ready accessibility through 
synthesis, wide range of chemical reactivity and broad spectrum of biological activity and variety 
of industrial applications. [27] 
 
The pyrazolone function is quite stable, and has inspired chemists to utilize this stable fragment 
in bioactive moieties to synthesize new compounds possessing biological activities. Pyrazolones 
have been reported to show a broad spectrum of biological activities including antibacterial [28], 
antioxidant [29], and anti-inflammatory [30] activities. Its derivatives possess a wide range of 
biological and physiological activities such as antitumor [31], analgesic [32] activities and industrial 
applications. Survey of literature in the recent past reveals that some pyrazolone derivatives also 
possess effect. 
 
After the work of Fischer and Knovenagel [33] in the late 19th century, the reaction of α, β-
unsaturated aldehydes and ketones with hydrazines became one of the most popular methods for 
the preparation of 2-pyrazolones. As a result, numerous substituted 2-pyrazolones have been 
synthesized, which has made possible structural activity relationship investigations of these 
substances. 
 
In view of the ongoing interest in the synthesis of nitrogen containing heterocyclic, the synthesis 
of biologically active new pyrazolone derivatives have been undertaken. 
 
                                            I-15                     I-16                      I-17 
The above three structures represents the tautomeric forms of pyrazolone nucleus. The 
application of present heterocyclic nomenclature to pyrazolone requires that nitrogen atoms be 
numbered one and two in each structure. 
 
The chemistry of pyrazolone began in 1883 when Knorrreported the first pyrazolone derivative. 
The reaction of phenyl hydrazine and ethylacetoacetate resulted in novel structure identified in 
1887 as 1-phenyl-3-methyl-5-pyrazolone. The Knorr pyrazole synthesis is the reaction of 
hydrazines with 1, 3 dicarbonyl compounds to provide the pyrazole or pyrazolone ring system. 
Pyrazolone is a five membered lactum ring containing two nitrogen and a ketone group in its 
ring. The prototype molecule, antipyrine was synthesized for clinical use in 1883. The 
methylated nitrogen derivative aminopyrine was introduced in 1897 and taken off from the 
market in the 1970s because of its property to form nitrosamines. Pyrazolone is an important 
pharmacophore which exhibits wide spread pharmacological properties. [34] 
1.2.1. MEDICINAL IMPORTANCE OF PYRAZOLONE NUCLEUS 
A large number of therapeutic agents are synthesized with the help of pyrazolone nucleus. 
During recent years there have been some interesting developments in the biological activities of 
pyrazolone derivatives. These compounds have special significance in the field of medicinal 
chemistry due to their remarkable pharmacological potentialities. [35] 
1.2.2. STRUCTURAL ACTIVITY RELATIONSHIP STUDY 
• Antioxidant studies shows that among pyrazolones having ring deactivating 
substituents, the highest activity was obtained with substituent having highest 
lipophilicity, lowest electron withdrawing power and highest polarisability (i.e., 
bromo compound).[36]  
• Among pyrazolone, substituents exerting activity in descending order of potency 
were found to be: m-NO2 >o, p-(CH3)2 > p-Cl >p-NO2 > o-COOH.  
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• Among o-substituted phenyl derivatives and o,p-disubstituted phenyl derivatives 
of pyrazolones, highest  activity was observed with substituent possessing highest 
lipophilicity (i.e., dimethyl compound).[37]  
• Considering the effect of orientation of nitro group in the phenyl ring of pyrazoles 
and pyrazolones on better activity, it was observed that compounds having nitro 
group in meta orientation gave better activity than o-isomer.  
• Among carboxyl derivatives of pyrazolones, p-isomer gave better activity.[38]  
 
1.2.3. SYNTHESIS OF PYRAZOLONE 
Pyrazolone consist of 5-membered containing two nitrogen, one ketone as hetero atoms.  
1. Preparation of the fully unsubstituted pyrazolone system from hydrazine hydrate and 
methyl (2E)-3-methoxyacrylate.[39] 
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2. Pyrazoles can be made from a 1,3-dicarbonyl component and a hydrazine or 
hydroxylamine respectively.[40]  
 
I-20 
3. 1-Phenyl, 2-pyrazolines was synthesized from the reaction between acrolein and phenyl 
hydrazine.[40] 
 
I-21 
4. Synthesis of 1-phenyl-3-methyl-5-pyrazolone by esters of acetic acid and phenyl 
hydrazine.[40]  
 
I-22 
5. 1,2- pyrazolines was synthesized from the reaction between acrylaldehyde and 
hydrazine.[40] 
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1.3. SCHIFF BASE 
 
A Schiff base, named after Hugo Schiff is a compound with a functional group that contains 
a carbon-nitrogen double bond with the nitrogen atom connected to an aryl or alkyl group, 
not hydrogen. Schiff bases in a broad sense have the general formula R1R2C=NR3, where R is 
an organic side chain. In this definition, Schiff base is synonymous with azomethine. Some 
restrict the term to the secondary aldimines (azomethines where the carbon is connected to a 
hydrogen atom), thus with the general formula RCH=NR'. 
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The chain on the nitrogen makes the Schiff base a stable imine. A schiff base derived from 
an aniline, where R3 is a phenyl or a substituted phenyl, can be called an anil.[41] 
1.3.1. MECHANISM OF SCHIFF BASE 
An  imine or schiff base forms, This is easily protonated to form a positively charged N at the 
former carbonyl O center. This serves as an excellent electron sink for decarboxylation reactions 
of beta-keto acids and illustrates an important point. Electrons in chemical reactions can be 
viewed as flowing from a source (such as a carboxyl group) to a sink (such as an nucleophilic 
carbonyl O or a positively charged N in a Schiff base). [42] 
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1.3.2. SYNTHESIS 
1. Schiff bases can be synthesized from an aromatic amine and a carbonyl compound 
by nucleophilic addition forming a hemiaminal, followed by a dehydration to generate an 
imine. In a typical reaction, 4,4'-diaminodiphenyl ether reacts with o-vanillin.[43] 
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2. Alkylation: 
1-Benzyloxy-4-nitro-benzene [44] 
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3. Esterification: 
(4-Nitro-phenyl)-acetic acid ethyl ester [45] 
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4. Béchamp-reduction:[46] 
5-Aminoindole 
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5. Bromination:[47] 
N-[4-(2-Bromo-acetyl)-phenyl]-2-phenyl-butyramide 
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6. C-C Coupling:[48] 
4-Nitro-biphenyl 
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7. In situ organic azide reagent synthesis:[49] 
Benzyl azide 
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8. Benzyl amine and triazole synthesis from crude azide product[50] 
 
I-34 
9. N-formylation:[51] 
N-Benzyl-N-methyl-formamide 
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10. Dehalogenation:[52] 
Benzenesulfinic acid 
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11. Trimethylsilylation:[53] 
Benzyloxy-trimethyl-silane 
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 12. Isonitrile formation:[54] 
 
I-38 
13. Reactions with CO:[55] 
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I-40 
1.4. DOCKING 
Molecular modelling encompasses all theoretical methods and computational techniques used to 
model or mimic the behaviour of molecules. The techniques are used in the fields of 
computational chemistry, computational biology and materials science for studying molecular 
systems ranging from small chemical systems to large biological molecules and material 
assemblies. The simplest calculations can be performed by hand, but inevitably computers are 
required to perform molecular modelling of any reasonably sized system. The common feature of 
molecular modelling techniques is the atomistic level description of the molecular systems; the 
lowest level of information is individual atoms or a small group of atoms. This is in contrast to 
quantum chemistry (also known as electronic structure calculations) where electrons are 
considered explicitly. The benefit of molecular modelling is that it reduces the complexity of the 
system, allowing many more particles (atoms) to be considered during simulations. [56, 57] 
In the field of molecular modeling, docking is a method which predicts the preferred orientation 
of one molecule to a second when bound to each other to form a stable complex. Knowledge of 
the preferred orientation in turn may be used to predict the strength of association or binding 
affinity between two molecules using for example scoring functions. [58] 
The associations between biologically relevant molecules such as proteins, nucleic acids, 
carbohydrates, and lipids play a central role in signal transduction. Furthermore, the relative 
orientation of the two interacting partners may affect the type of signal produced (e.g., agonism 
vs antagonism). Therefore docking is useful for predicting both the strength and type of signal 
produced. [59] 
Docking is frequently used to predict the binding orientation of small molecule drug candidates 
to their protein targets in order to in turn predict the affinity and activity of the small molecule. 
Hence docking plays an important role in the rational design of drugs. Given the biological and 
pharmaceutical significance of molecular docking, considerable efforts have been directed 
towards improving the methods used to predict docking. [60] 
Some glossary for docking, 
• Receptor or host or lock – The "receiving" molecule, most commonly a protein or other 
biopolymer.  
• Ligand or guest or key – The complementary partner molecule which binds to the receptor. 
Ligands are most often small molecules but could also be another biopolymer.  
• Docking – Computational simulation of a candidate ligand binding to a receptor.  
• Binding mode – The orientation of the ligand relative to the receptor as well as the 
conformation of the ligand and receptor when bound to each other.  
• Pose – A candidate binding mode.  
• Scoring – The process of evaluating a particular pose by counting the number of favorable 
intermolecular interactions such as hydrogen bonds and hydrophobic contacts.  
• Ranking – The process of classifying which ligands are most likely to interact favorably to a 
particular receptor based on the predicted free-energy of binding. [61] 
Schematic diagram illustrating the docking of a small molecule ligand (brown) to a protein 
receptor (green) to produce a complex. 
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Small molecule docked to a protein 
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1.4.1. DOCKING APPROACHES [62] 
Two approaches are particularly popular within the molecular docking community. One 
approach uses a matching technique that describes the protein and the ligand as complementary 
surfaces. The second approach simulates the actual docking process in which the ligand-protein 
pairwise interaction energies are calculated. Both approaches have significant advantages as well 
as some limitations. These are outlined below. 
 Shape complementarity 
Geometric matching, shape complementarity methods describe the protein and ligand as a set of 
features that make them dockable. These features may include molecular surface, 
complementary surface descriptors. In this case, the receptor’s molecular surface is described in 
terms of its solvent-accessible surface area and the ligand’s molecular surface is described in 
terms of its matching surface description. The complementarity between the two surfaces 
amounts to the shape matching description that may help finding the complementary pose of 
docking the target and the ligand molecules. Another approach is to describe the hydrophobic 
features of the protein using turns in the main chain atoms. Yet another approach is to use a 
fourier shape descriptor technique, where as the shape complementarity based approaches are 
typically fast and robust, they cannot usually model the movements or dynamic changes in the 
ligand, protein conformations accurately, although recent developments allow these methods to 
investigate ligand flexibility. Shape complementarity methods can quickly scan through several 
thousand ligands in a matter of seconds and actually figure out whether they can bind at the 
protein’s active site, and are usually scalable to even protein-protein interactions. They are also 
much more amenable to pharmacophore based approaches, since they use geometric descriptions 
of the ligands to find optimal binding. 
 Simulation 
The simulation of the docking process as such is a much more complicated process. In this 
approach, the protein and the ligand are separated by some physical distance, and the ligand 
finds its position into the protein’s active site after a certain number of “moves” in its 
conformational space. The moves incorporate rigid body transformations such as translations and 
rotations, as well as internal changes to the ligand’s structure including torsion angle rotations. 
Each of these moves in the conformation space of the ligand induces a total energetic cost of the 
system, and hence after every move the total energy of the system is calculated. The obvious 
advantage of the method is that it is more amenable to incorporate ligand flexibility into its 
modeling whereas shape complementarity techniques have to use some ingenious methods to 
incorporate flexibility in ligands. Another advantage is that the process is physically closer to 
what happens in reality, when the protein and ligand approach each other after molecular 
recognition. A clear disadvantage of this technique is that it takes longer time to evaluate the 
optimal pose of binding since they have to explore a rather large energy landscape. However 
grid-based techniques as well as fast optimization methods have significantly ameliorated these 
problems. 
1.4.2. MECHANICS OF DOCKING [63] 
To perform a docking screen, the first requirement is a structure of the protein of interest. 
Usually the structure has been determined using a biophysical technique such as x-ray 
crystallography or less often, NMR spectroscopy. This protein structure and a database of 
potential ligands serve as inputs to a docking program. The success of a docking program 
depends on two components: the search algorithm and the scoring function. 
 Search algorithm 
The search space in theory consists of all possible orientations and conformations of the protein 
paired with the ligand. However in practice with current computational resources, it is 
impossible to exhaustively explore the search space, this would involve enumerating all possible 
distortions of each molecule (molecules are dynamic and exist in an ensemble of conformational 
states) and all possible rotational and translational orientations of the ligand relative to the 
protein at a given level of granularity. Most docking programs in use account for a flexible 
ligand, and several attempt to model a flexible protein receptor. Each "snapshot" of the pair is 
referred to as a pose. 
A variety of conformational search strategies have been applied to the ligand and to the receptor. 
These include: 
• Systematic or stochastic torsional searches about rotatable bonds. 
• Molecular dynamics simulations. 
• Genetic algorithms to "evolve" new low energy conformations. 
 Ligand flexibility 
Conformations of the ligand may be generated in the absence of the receptor and subsequently 
docked or conformations may be generated on-the-fly in the presence of the receptor binding 
cavity or with full rotational flexibility of every dihedral angle using fragment based docking. 
Force field energy evaluation are most often used to select energetically reasonable 
conformations, but knowledge-based methods have also been used. 
 Receptor flexibility 
Computational capacity has increased dramatically over the last decade making possible the use 
of more sophisticated and computationally intensive methods in computer-assisted drug design. 
However, dealing with receptor flexibility in docking methodologies is still a thorny issue. The 
main reason behind this difficulty is the large number of degrees of freedom that have to be 
considered in this kind of calculations. Neglecting it, however, leads to poor docking results in 
terms of binding pose prediction. 
Multiple static structures experimentally determined for the same protein in different 
conformations are often used to emulate receptor flexibility. Alternatively rotamer libraries of 
amino acid side chains that surround the binding cavity may be searched to generate alternate but 
energetically reasonable protein conformations. 
1.4.3. SCORING FUNCTION [64] 
The scoring function takes a pose as input and returns a number indicating that, the pose 
represents a favorable binding interaction. 
Most scoring functions are physics-based molecular mechanics force fields that estimate the 
energy of the pose; a low (negative) energy indicates a stable system and thus a likely binding 
interaction. An alternative approach is to derive a statistical potential for interactions from a 
large database of protein-ligand complexes, such as the Protein Data Bank, and evaluate the fit of 
the pose according to this inferred potential. 
There are a large number of structures from X-ray crystallography for complexes between 
proteins and high affinity ligands, but comparatively fewer for low affinity ligands as the later 
complexes tend to be less stable and therefore more difficult to crystallize. Scoring functions 
trained with this data can dock high affinity ligands correctly, but they will also give plausible 
docked conformations for ligands that do not bind. This gives a large number of false positive 
hits, i.e., ligands predicted to bind to the proteins that actually don’t when placed together in a 
test tube. 
One way to reduce the number of false positives is to recalculate the energy of the top scoring 
poses using (potentially) more accurate but computationally more intensive techniques such as 
generalized born or poisson-boltzmann methods. 
1.4.4. APPLICATIONS [65]   
A binding interaction between a small molecule ligand and an enzyme protein may result in 
activation or inhibition of the enzyme. If the protein is a receptor, ligand binding may result in 
agonism or antagonism. Docking is most commonly used in the field of drug design, most drugs 
are small organic molecules, and docking may be applied to: 
• Hit identification – docking combined with a scoring function can be used to quickly 
screen large databases of potential drugs insilico to identify molecules that are likely to 
bind to protein target of interest (virtual screening). 
• Lead optimization – docking can be used to predict in where and in which relative 
orientation a ligand binds to a protein (also referred to as the binding mode or pose). This 
information may in turn be used to design more potent and selective analogs. 
• Bioremediation – Protein ligand docking can also be used to predict pollutants that can be 
degraded by enzymes. 
1.5. ANTIMICROBIAL 
1.5.1. ANTIBACTERIAL 
Synthetic antibacterial compounds are divided into two major classes: typical agents and 
systemic agents. The typical agents are termed disinfectants, antiseptics, and preservatives, 
depending on how they are used. Antiseptics and disinfectants differ from systemic agents in that 
they show little selective toxicity between the microbes and the host. Furthermore, most of them 
do not aid wound healing and may even impair it. Nevertheless, there are indispensable uses for 
disinfectants in hospital sanitation, including sterilization of surgical instruments, public health 
methods, and in the home. Antiseptics have important applications in the preoperative 
preparation of the both surgeons and patients. They also are used in treating local infections 
caused by microorganisms refractive to systemic antimicrobial agents. [66] 
 
 Mechanisms of bacterial resistance 
The outer memberane of gram-negative bacteria is composed of lipopolysaccharide, proteins, 
and lipids. It presents a barrier to many chemical agents, including quaternary ammonium 
compounds and triphenylmethane dyes. In contrast, the cytoplasmic membrane of gram-positive 
bacteria, excepting spores and mycobacteria, has greater permeability to most agents. Spores 
have a special coat and/or cortex that may not be permeable to hydrogen peroxide and chlorine 
disinfectants. Bacterial cells may also have efflux mechanisms that extrude agents such as 
quaternary ammonium compounds, dyes, and mercury compounds from their interiors. [67] 
 Systemic synthetic antibacterial 
Prontosil rubrum, sulfonamido-azo dye, was the first clinically useful systemic antibacterial 
agent to be discovered. This discovery was done in the early 1930s and the development of 
sulfonamides and sulfones as a class of antibacterial agents. Their broad antimicrobial spectrum 
provided, for the first time, drugs for the cure and prevention of a variety of bacterial infections; 
their widespread clinical use brought about a sharp decline in morbidity and mortality of 
treatable infectious diseases, and thus proved of great medical and public health importance. 
Recognition of the inhibition of the action of sulphonamides by extracts which was down to be 
attributed to the presence of p-aminobenzoic acid (PABA), required in folate biosynthesis, was 
the first clear demonstration of metabolites antagonism as a mechanism of drug action; this 
provided the long sought after mechanistic basis for drug action.[68] 
 
1.5.2. ANTIFUNGAL 
The first antifungal discovered in 1939 was griseofulvin. The introduction of griseofulvin was 
followed in 1960 by that of amphotericin B, which is still the “gold standard “for the treatment of 
severe systemic mycoses. 
Fungal infection are caused by eukaryotic organisms and for that reason they generally present 
more difficult therapeutic problems than do bacterial infections. The fungal cell wall may be 
considered to be a prime target for selectively toxic antifungal agent because of its chitin 
structure, absent from human cells. Day by day number of antifungal agent are preparing and 
against fungi. 
Of the five fundamental kingdoms of Life, the kingdom fungi are arguably the most diverse and 
prevalent. Unlike the kingdom monera (containing bacteria),   fungi are eukaryotic organisms. 
Thus the issue of selectivity predominates in the guest for safe and effective chemotherapeutic 
remedies for diseases caused by fungi. Chemotherapy, there is a risk-reward ratio to be taken 
into account; in the context of fungal infections, this ratio may vary greatly, from minor 
irritations such as athlete’s foot to life-threatening systemic infections such as those caused by 
Aspergillus fumigatus. This addresses medicinal aspects of the treatment of fungal diseases of all 
types, but because most recent research has been directed toward the treatment of systemic 
infections, emphasis is placed on this aspect. [69] 
1.6. ANTIOXIDANT 
The World Health Organization (WHO) has estimated that 80% of the earth’s inhabitants rely on 
traditional medicine for their primary health care needs, and most of this therapy involves the use 
of plant extracts and their active components. Under stress, our bodies produce more reactive 
oxygen species (ROS) than enzymatic antioxidants and non-enzymatic antioxidants. This 
imbalance leads to cell damage and health problems. A lack of antioxidants, which can quench 
the reactive free radicals, facilitates the development of degenerative diseases, including cancers 
and inflammatory diseases. One solution to this problem is to supplement the diet with 
antioxidant compounds. The antioxidants can therefore serve as a type of preventive medicine. 
Recent reports indicate that there is an inverse relationship between the dietary intake of 
antioxidant-rich foods and the incidence of human diseases. However, synthetic antioxidants 
have been widely used as antioxidants in the food industry. [70] 
Antioxidants, including pyrazolone compounds have diverse biological effects, such as anti-
inflammatory, anti-cancer effects, as a result of their antioxidant activiy. 
An antioxidant is a molecule capable of inhibiting the oxidation of other molecules. Oxidation is 
a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation 
reactions can produce free radicals. In turn, these radicals can start chain reactions that damage 
cells. Antioxidants terminate these chain reactions by removing free radical intermediates, and 
inhibit other oxidation reactions. They do this by being oxidized themselves, so antioxidants are 
often reducing agents. [71] 
Although oxidation reactions are crucial for life, they can also be damaging; hence, plants and 
animals maintain complex systems of multiple types of antioxidants. Low levels of antioxidants, 
or inhibition of the antioxidant enzymes, cause oxidative stress and damage or kill cells. 
As oxidative stress might be an important part of many human diseases, the use of antioxidants 
in pharmacology is intensively studied, particularly as treatments for stoke and inflammatory 
diseases. However, it is unknown whether oxidative stress is the cause or the consequence of 
disease. 
Reactive oxygen species (ROS), capable of causing damage to DNA, has been associated with 
carcinogenesis, coronary heart disease, inflammatory disease and many other health problems 
related to advancing age. In low concentrations, synthetic antioxidants are also in use for many 
industrial processes e.g. inhibition of radical formation for preventing premature polymerization 
during processing, storage and transportation of unsaturated monomers. They exert their effects 
by scavenging or preventing he generation of ROS which can protect the formation of free 
radicals and retard the progress of many chronic diseases including cancer and inflammation 
diseases. [72] 
Some of the methods available for knowing antioxidant activity are, 
• Determination of DPPH (1-1-diphenyl 2-picryl hydrazyl) radical-scavenging activity 
• Determination of hydroxyl radical-scavenging activity 
• Determination of nitric oxide radical-scavenging activity 
• ABTS radical scavenging assay 
• FRAP radical scavenging assay 
1.7. CANCER 
Normal cells in our body follow an orderly path of growth, division and death. Cancer is a class 
of diseases characterized by out-of-control cell growth which harms the body by forming lumps 
or masses of tissue called tumors. Tumors are invasive, aggressive and mostly metastatic. 
Tumors that stay in one spot and show limited growth are called benign which can often be 
removed, and, in most cases, they do not come back. Also, cells in benign tumors do not spread 
to other parts of the body. Cancer is, thus, the result of cells that uncontrollably grow and do not 
die. [73] 
1.7.1. CAUSES OF CANCER 
Cancer is a diverse class of diseases which differ widely in their causes and biology. The 
common thread in all known cancers is the acquisition of abnormalities in the genetic material of 
the cancer cell and its progency. Research into the pathogenesis of cancer can be divided into 
three broad areas of focus. The first area of research focuses on the agents and events which 
cause or facilitate genetic changes in cells destined to become cancer. Second, it is important to 
uncover the precise nature of the genetic damage, and the genes which are affected by it. The 
third focus is on the consequences of those genetic changes on the biology of the cell, both in 
generating the defining properties of a cancer cell, and in facilitating additional genetic events, 
leading to further progression of the cancer. 
 Chemical carcinogens: Cancer pathogenesis is traceable back to DNA mutations that 
impact cell growth and metastasis.Substances that cause DNA mutations are known as 
mutagens, and mutagens that cause cancers are known as carcinogens. Particular 
substances have been linked to specific types of cancer. Tobacco smoking is associated 
with lung cancer and bladder cancer. Prolonged exposure to asbestos fibers is associated 
with mesothelioma. Many mutagens are also carcinogens, but some carcinogens are not 
mutagens. Alcohol is an example of a chemical carcinogen that is not a mutagen. Such 
chemicals are thought to promote cancers through their stimulating effect on the rate of 
cell mitosis. 
 Ionizing radiation:   Sources of ionizing radiation, such as radon gas, can cause cancer. 
Prolonged exposure to ultraviolet radiation from the sun can lead to melanoma and other 
skin malignancies. 
 Hormonal imbalance: Some hormones can act in a similar manner to non mutagenic 
carcinogens in that they may stimulate excessive cell growth. A well established example 
is the role of hyper estrogenic states in promoting endometrial cancer. 
 Immune system dysfunction: HIV is associated with a number of malignancies, 
including kaposi’s sarcoma, non-hodgkin’s lymphoma, and HPV associated malignancies 
such as anal cancer and cervical cancer. AIDS defining illnesses have long included these 
diagnoses. The increased incidence of malignancies in HIV patients points to the 
breakdown of immune surveillance as a possible etiology of cancer. Certain other 
immune deficiency states (e.g. common variable immunodeficiency and IgA deficiency) 
are also associated with increased risk of malignancy. 
 Heredity: Most forms of cancer are “sporadic”, and have no basis in heredity. There are, 
however, a number of recognised syndromes of cancer with a hereditary component, 
often a defective tumor suppressor allele. 
 Other causes: A few types of cancer in non-humans have been found to be caused by the 
tumor cells themselves. This phenomenon is seen in sticker’s sarcoma, also known as 
canine transmissible venereal tumor.[74] 
 
1.7.2. TYPES OF CANCER 
• Carcinoma - cancer of the skin or tissues that line or cover internal organs. 
• Sarcoma - cancer that starts in bone, cartilage, fat, muscle, blood vessels, or other 
connective or supportive tissue. 
• Leukemia - cancer that starts in blood-forming tissue such as the bone marrow. 
• Lymphoma and myeloma - cancers that begin in the cells of the immune system. 
• Central nervous system cancers - cancers that begin in the tissues of the brain and 
spinal cord. 
• Adenoma - cancers that arise in the thyroid, the pituitary gland, the adrenal gland, and 
other glandular tissues. 
1.7.3. TREATMENT 
y Surgery 
y Radiation therapy 
y Immunotherapy 
y Hormone therapy 
y Gene therapy 
y Chemotherapy 
1.7.4. CANCER CHEMOTHERAPY 
Chemotherapy refers to the treatment of an ailment by chemicals especially by killing micro-
organisms or cancerous cells. Antineoplastic drugs are used in cancer chemotherapy. A single 
"cure" for cancer has proved elusive since there is not a single type of cancer but more than 
hundred different types of cancer. Though the available anticancer drugs have distinct 
mechanisms of action which may vary in their effects on different types of normal and cancer 
cells, their toxicity to normal rapidly growing cells in the intestinal and bone marrow areas and 
the problem of resistance pose a great problem. For this reason cancer chemotherapy may consist 
of using a combination of several drugs for varying lengths of time. [75] 
Based on their mechanism of action, chemotherapy agents can be divided into three main 
categories as follows: 
 Drugs that stop the synthesis of DNA building blocks 
 e.g. methotrexate, fluorouracil, hydroxyurea, mercaptopurine etc. 
 Drugs that directly damage the DNA  
e.g. cisplatin, antibiotics – daunorubicin, doxorubicin, etoposide etc. 
 Drugs that affect the synthesis or breakdown of the mitotic spindles 
e.g. vinblastine, vincristine, paclitaxel etc. 
1.8. TUBERCULOSIS 
Tuberculosis (TB), which was referred to as "consumption” in the early days due to the wasting 
nature of this disease , is an infectious disease caused by bacteria whose scientific name is 
Mycobacterium tuberculosis. It was first isolated by a german physician named robert koch in 
1882, who received the nobel prize for this discovery. Tuberculosis is transmitted primarily from 
person to person by breathing infected air during close contact and it mainly affects the lungs but 
also can involve almost any organ of the body. Another form of tuberculosis called atypical 
tuberculosis is transmitted by drinking unpasteurized milk contaminated with Mycobacterium 
bovis. [76]  
1.8.1. TREATMENT OF TB 
Standard "short" course treatment for TB consists of a six-month regimen (two months treatment 
with isoniazid, rifampin and pyrazinamide followed by four months of isoniazid and rifampin). 
Ethambutol or streptomycin may be added based on the drug sensitivity of the patient. Multiple 
drug therapy is adopted due to the rapid development of resistance to single drug regimen. For 
latent tuberculosis, the standard treatment of six to nine months of isoniazid alone is preferred. 
[77] 
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2. LITERATURE REVIEW 
Literature survey suggest that extensive synthetic work on benzothiazole containing pyrazolone 
derivatives is going on in recent years because of their pronounced biological activities such as 
anti-microbial, antitubercular, antioxidant and cytotoxic activities. 
2.1. BENZOTHIAZOLE NUCLEUS 
      2.1.1. Antimicrobial activity 
1. Gupta et al., 2009[78] has reported synthesis of series of pyrimido [2,1-b] benzothiazoles 
exhibiting as potent antimicrobial activity against E.coli and  Enterobacter as test 
organisms at conc 100μg per disc using vancomycine and meropenam as standard drug. 
 
                         II-1 
2. Kumbhare et al., 2009[79] has synthesized new benzothiozole and benzisoxazole from 2-
amino 5, 6-hydroxybenzothiazole, 6-hydroxy-3-methyl-1, 2-benzisoxal and different 
dihaloalkanes showed as antimicrobial activity against Staphylococcus aureus, and E. 
coli by disc diffusion method. Ciprofloxacin (10μg/ml) were used as standard drug. 
 
II-2 
3. Murthi et al., 2008[80] has synthesized some new 2-mercaptobenzothiazoles.This 
benzothiazole ring exhibit as antimicrobial activity against Aspergillus flavus,and 
Candida albicans. Fluconazole (10μg/ml) were used as standard drug. 
 
II-3 
4. Rajeeva et al., 2009[81] has synthesized some new 2-substituted benzothiazole derivatives 
exhibit as antimicrobial activity against E. coli, S. aureus. Ofloxacine (100μg/ml) were 
used as standard drug. 
 
II-4 
5. Maharan et al., 2007[82] has synthesized series of benzothiazole-2-yl-dithiocarbamates 
showed as potent antimicrobial activity against Aspergillus flavus and Candida albicans. 
griciofulvin (100μg/ml) were used as standard drug. 
 
II-5 
6. Amir et al., 2009[83] has synthesized 1, 3, 4-thiadiazole and imidazolline derivatives 
exhibit as antimicrobial activity against B. subtilis, E. coli and P.aeruginosa by disc 
diffusion method at conc. 100μg/ml. 
 
II-6 
7. Nagarjuna et al., 2009[84] has synthesized benzothiazole substituted thiazolidinone. 
Compounds showed as antimicrobial activity against E. coli, S. aureus  and C. albicans  
Aspergillus flavus. Ofloxacine (50μg/ml) and ketokonazole (50μg/ml) were used as 
standard. 
 
II-7 
           
      2.1.2. Anti-cancer activity 
8. Kini et al., 2007[85] has reported refluxed o-aminophenols with substituted benzoic acid in 
presence of polyphosphoric acid at higher temperature to get aryl substituted 
benzothiazoles which showed as anticancer activity on HL-60 cell lines. 
 
II-8 
9. Stanton et al., 2008[86] has synthesized benzothiazole containing phthalimide and studied 
their anti-cancer activity on human carcinoma cell lines. 
 
         II-9 
10. Wang et al., 2006[87] has synthesized carbon 11 labeled fluorinated 2-aryl benzothiazoles 
used for protein emission tomography (PET) to image tyrocinekinese in cancer and 
studied their anti-cancer activity on human carcinoma cell lines.  
 
II-10 
11. Gupta et al., 2010[88] has synthesized benzothiazole derivatives and evaluated for in vitro 
cytotoxic activity against HL-60 and U- 937 cell lines using 5-flurouracil, and cisplatin as 
std. The QSAR study showed that increase in hydrogen donor count is conductive for 
cytotoxic activity of benzothiazole derivatives against HL-60 cell lines. 
                       
 
II-11 
12. Hutchinson et al., 2001[89] have been synthesized Fluorinated analogues of 2-(4-
aminophenyl) benzothiazoles, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole exhibit 
selective and potent anticancer activity on U- 937 cell lines. 
 
II-12 
      2.1.3. Anti-oxidant activity 
13. Sreenivasa et al., 2009[90] has synthesized fllurobenzothiazole comprising sulfonamide 
pyrazole derivitives. They screened synthesized for antioxidant activity by using DPPH 
method. 
 
 
II-13 
14. Pattan et al., 2005[91] has synthesized 2-amino [5` (4-sulphonylbenzylidine)-2, 4-
thiazolidnedione]-7-chloro-6-flurobenzothiazole series and screened for their antioxidant 
activity by FRAP method. 
 
II-14 
15. Radchenka et al., 2009[92] was reported benzthiazole containing compounds as potent 
anti-oxidant agents by using DPPH method. 
 
 
II-15 
16. Smith et al., 2003[93] was reported benzthiazole containing peptides as potent anti-oxidant 
agents by using DPPH method. 
 
II-16 
17. Sohail Saeed et al.,  2010[94] has reported a series of thiourea derivatives bearing 
benzthiazole moiety were efficiently synthesized and evaluated for antioxidant agents by 
using ABTS method. 
 
II-17 
18. Samir Bondock et al., 2001[95] has reported synthesis of substituted heterocyclic 
incorporating benzthiazole moiety as potent antioxidant agents by using DPPH method. 
 
II-18 
19. Stevens et al., 2007[96] has reported a series of sulfamate salt derivatives of the potent and 
selective 2-(4-aminophenyl) benzothiazole as antioxidant agents by using ABTS method. 
 
II-19 
20. Albert Sun et al., 2008[97] has reported synthesis of benzothiazole containing phthalic 
imide derivative exhibiting in-vitro antioxidant agents by using DPPH method. 
 
II-20 
      2.1.4. Antitubercular activity 
21. Evindar et al., 2006[98] has reported synthesis of benzothiazole moiety showed as 
antitubercular activity by using amplified mycobacterium tuberculosis direct assay 
method. 
 
II-21 
22. Joyce et al., 2004[99] has reported synthesis of benzothiazole derivatives exhibit as 
antitubercular activity by using agar dilution assay method. 
 
II-22 
23. Batey et al., 2003[100] has reported synthesis of benzothiazole showed as antitubercular 
activity by using microplate alamar blue assay method. 
 
II-23 
24. Rudawar et al., 2005[101] has reported synthesis of benzothiazole compounds exhibit as 
antitubercular activity by using resazurin microplate assay method.  
 
II-24 
25. Lawesson et al., 1977[102] has reported synthesis of benzothiazole derivatives exhibit as 
antitubercular activity by using amplified mycobacterium tuberculosis direct assay 
method. 
 
II-25 
26. Cava et al., 1985[103] has reported synthesis of benzothiazole derivatives exhibit as 
antitubercular activity by using agar dilution assay method. 
 
II-26 
27. Foreman et al., 2000[104] has reported synthesis of benzothiazole derivatives exhibit as 
antitubercular activity by using microplate alamar blue assay method. 
 
II-27 
28. Willis et al., 2007[105] has reported synthesis of benzothiazole derivatives exhibit as 
antitubercular activity by using resazurin microplate assay method. 
 
II-28 
2.2. PYRAZOLONE NUCLEUS 
       2.2.1. Antimicrobial activity 
29. Furniss et al., 1998[106] has reported synthesis of 1-[1H-imidazol-1-yl(phenyl)methyl]-5-
methyl-1,2-dihydro-3H-pyrazol-3-one showed as antimicrobial activity against E.coli and  
Enterobacter as test organisms at conc 100μg per disc using vancomycine and 
meropenam as standard drug by disc diffusion method. 
 
II-29 
30. Harish et al., 2007[107] has reported synthesis of 1-[1H-imidazol-1-yl(phenyl)methyl]-5-
methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one showed as antimicrobial activity against 
Staphylococcus aureus and E. coli by disc diffusion method. Ciprofloxacin (10μg/ml) 
were used as standard drug. 
 
II-30 
 
31. Dubois et al., 2004[108] has reported synthesis of 2-[1H-imidazol-1-yl(phenyl)methyl]-3 
methyl-5-oxo-2,5-dihydro-1H-pyrazole-1-carboxamide showed as antimicrobial activity 
against Aspergillus flavus,and Candida albicans by disc diffusion method. Fluconazole 
(10μg/ml) were used as standard drug. 
 
II-31 
32. Sushma et al., 2007[109] has reported synthesis of 1-[1H-benzotriazol-1-
yl(phenyl)methyl]-5-methyl-1,2-dihydro-3H-pyrazol-3-one showed as antimicrobial 
activity against E. coli, S. aureus. Ofloxacine (100μg/ml) were used as standard drug. 
 
II-32 
33. Winter et al., 1962[110] has reported synthesis of 1-[1H-benzotriazol-1-yl (phenyl) 
methyl]-4-methyl-2-phenyl-1, 2-dihydro-3H-pyrazol-3-one showed as antimicrobial 
activity against Aspergillus flavus and Candida albicans. griciofulvin (50μg/ml) were 
used as standard drug. 
 
II-33 
 
34. Arpana et al., 2007[111] has reported synthesis of 2-[1H-benzotriazol-1-yl(phenyl)methyl]-
4-methyl-5-oxo-2,5-dihydro-1H-pyrazole-1-carboxamide showed as antimicrobial 
activity against B. subtilis, E. coli and P.aeruginosa by disc diffusion method at conc. 
100μg/ml.. 
 
II-34 
35. Pramila et al., 2007[112]  has reported synthesis of 1-[1H-benzimidazol-1-
yl(phenyl)methyl]-5-methyl-1,2-dihydro-3H-pyrazol-3-one showed as antimicrobial 
activity against E. coli, S. aureus  and C. albicans  Aspergillus flavus. Ofloxacine 
(10μg/ml) and ketokonazole (10μg/ml) were used as std. 
 
 
II-35 
 
36. Melmed et al., 2004[113] has reported synthesis of 1-[1H-benzimidazol-1-
yl(phenyl)methyl]-5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one showed as 
antimicrobial activity against Aspergillus flavus and Candida albicans. griciofulvin 
(10μg/ml) were used as standard drug.. 
 
II-36 
37. Rainsford et al., 2001[114] has reported synthesis of 2-[1H-benzimidazol-1-
yl(phenyl)methyl]-3-methyl-5-oxo-2,5-dihydro-1H-pyrazole-1-carboxamide showed as 
antimicrobial activity against E. coli. Ofloxacine (100μg/ml) were used as standard drug. 
 
II-37 
      2.2.2. Anti-cancer activity  
38. Pan et al., 2001[115] has reported synthesis of 1-phenyl-3-methyl-4- (2 -
hydroxylbenzylidenehydrazine)-p-methylbenzylidene-5- pyrazolone exhibit selective and 
potent anticancer activity by using MTT assay method. 
 
II-38 
39. Bertenshaw et al., 1997[116] has reported synthesis of 1, 3-di phenyl-4- (2 -
hydroxylbenzylidenehydrazine)-ethidine-5- pyrazolone exhibit selective and potent 
anticancer activity by using flow cytometric assay for cell apoptosis. 
 
II-39 
40. Cirillo  et al., 2002[117] has reported synthesis of 1-Phenyl-3- methyl-4-propionyl-5-
pryazolone semicarbazone exhibit selective and potent anticancer activity by using lactate 
dehydrogenase release assay method. 
 
II-40 
 
41. Amici et al., 2004[118] has reported synthesis of 1, 3-di phenyl-4- (p -
nitrobenzoylhydrazide)-ethidine-5- pyrazolone exhibit selective and potent anticancer 
activity by using p-glycoprotein pump in MCF-7R cells assay method. 
 
II-41 
42. Sasaki et al., 2004[119] has reported synthesis of 1,3-di phenyl-4- (2 –ethylamino-6H -1, 
3,4-th iadiazine-5- yl ene)-5- pyrazolone exhibit selective and potent anticancer activity 
by using insulin-like growth factor-I induced kinase receptor activation assay . 
 
II-42 
43. Ashour et al., 2005[120] has reported synthesis of 1-Phenyl-3- methyl-4- 
(ethylaminoformylhydrazide)-p- methylbenzylidene-5- pyrazolone exhibit selective and 
potent anticancer activity by using insulin-like gD trkA induced kinase receptor 
activation assay method. 
 
II-43 
 
44. Zhang et al., 2006[121] has reported synthesis of 1-phenyl-3- methyl-4-
(methylaminoformylhydrazide)-p- methylbenzylidene-5- pyrazolone exhibit selective and 
potent anticancer activity by using tumor endothelial cell tube formation assay. 
 
II-44 
      2.2.3. Anti-oxidant activity  
45. Ovalles  et al., 2006[122] has reported synthesis of 1,3-di phenyl-4- propionyl-5- 
pyrazolone semicarbazone as antioxidant agents by using ABTS method. 
 
II-45 
46. Naito  et al., 2002[123] has reported synthesis of [CuL(EtOH)]1-Phenyl-3- methyl-4- 
(salicyclidenehydrazide)-propylidene-5- pyrazolone as antioxidant agents by using FRAP 
method. 
 
II-46 
47. Deng et al., 2004[124] has reported synthesis of [CuL(EtOH)]1-Phenyl-3- methyl-4- (2 -
hydroxylbenzylidenehydrazine)-propylidene-5- pyrazolone as antioxidant agents by using 
ABTS method.  
 
II-47 
48. Liang et al., 2002[125] has reported synthesis of 1-Phenyl-3- methyl-4- (2 -
hydroxylbenzoylhydrazide)-propylidene-5- pyrazolone as antioxidant agents by using 
ABTS method. 
 
II-48 
49. Jia et al., 2007[126] has reported synthesis of 1-Phenyl-3- methyl-4- (2 -hy 
droxylbenzylidenehydrazine)-propylidene-5- pyrazolone as antioxidant agents. 
 
II-49 
50. Tu et al., 2003[127] has reported synthesis of 1-Phenyl-3- methyl-4- 
(methylaminoformylhydrazide)-propylidene-5- pyrazolone as antioxidant agents by using 
DPPH method. . 
 
II-50 
      2.2.4. Antitubercular activity 
51. Sandrini et al., 2002[128] has reported synthesis of 4-amino-2,3-dimethyl-1-phenyl-1,2-
dihydropyrazol-3-one showed as antitubercular activity by using resazurin microplate 
assay method. 
 
II-51 
52. Erol et al., 2001[129] has reported synthesis of 2-chloro-N-(2, 5-dihydro-2, 3-dimethyl-5-
oxo-1-phenyl-1H-pyrazol-4-yl)-acetamide showed as antitubercular activity by using 
amplified mycobacterium tuberculosis direct assay method. 
 
II-52 
 
 
53. Fahmy et al., 2003[130] has reported synthesis of pyrazolone compounds showed as 
antitubercular activity by using resazurin microplate assay method. 
 
II-53 
54. Bekhit et al., 2004[131] has reported synthesis of pyrazolone moiety showed as 
antitubercular activity by using microplate alamar blue assay method. 
 
 
II-54 
55. Sahin et al., 2004[132] has reported synthesis of pyrazolone moiety exhibit as 
antitubercular activity by using microplate alamar blue assay method. 
 
 
II-55 
 
56. Hawash et al., 2006[133] has reported synthesis of pyrazolone moiety exhibit as 
antitubercular activity by using amplified mycobacterium tuberculosis direct assay 
method. 
 
II-56 
57. Rismondo et al., 2007[134] has reported synthesis of pyrazolone moiety showed as 
antitubercular activity by using resazurin microplate assay method. 
 
 
II-57 
58. Varga et al., 2008[135] has reported synthesis of pyrazolone moiety exhibit as 
antitubercular activity by using agar dilution assay method. 
 
II-58 
59. Dannhardt et al., 2001[136] has reported synthesis of 2-(5-amino-1, 3, 4-thiadiazol-2-
ylthio)-N-(2,5-dihydro-2,3-dimethyl-5-oxo-1-phenyl-1H-pyrazol-4-yl) acetamide showed 
as antitubercular activity by using microplate alamar blue assay method. 
 
II-59 
60. Lown et al., 2002[137] has reported synthesis of 2-cyano-N-(2, 5-dihydro-2, 3-dimethyl-5-
oxo-1-phenyl-1H-pyrazol-4-yl) acetamide showed as antitubercular activity by using 
amplified mycobacterium tuberculosis direct assay method. 
 
II-60 
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3. AIM AND OBJECTIVES 
 
Tuberculosis is a major health problem worldwide, with approximately 1.7 million people dying 
annually from the disease. The long current drug regimen, the emergence of drug resistant strains 
and HIV co-infection have resulted in a resurgence in research efforts to address the urgent need 
for new antituberculosis drugs. The success of chemotherapy is strictly related to the use of drug 
combinations. In the initial treatment, it is a fundamental rule to use atleast three drugs, to avoid 
the emergence of bacterial resistance, which is the principle cause of therapeutic failure. The 
development of resistance to antibiotics and the changing clinical pattern of bacterial infections 
are constant challenge to drug research. 
From the chemotherapeutic point of view, there are two sources of new chemical entities. The 
first is the extraordinary diversity provided by natural products. The second results from the 
design of new or the modification of synthetic transformations. 
Benzothiazole, Pyrazolone have attracted continuing interest because of their varied biological 
activities. 
Benzothiazoles are bicyclic ring system with multiple applications. Various benzothiazoles such 
as 2-aryl benzothiazole received much attention due to unique structure and its exhibit as 
cytotoxic on cancer cells, antimicrobial, antioxidant, antitubercular [14] agents.  
Pyrazolone derivatives are an important class of heterocyclic compounds. In recent years, the 
pyrazolone nucleus containing compounds involved in research aimed at evaluating new 
products that possess biological activities, such as antimicrobial, in-vitro antioxidant, 
antitubercular and anticancer agents. 
Based on the literatures we are planning to link both Benzthiazole and Pyrazolone nucleus for 
better biological activities like anti-microbial, in-vitro anticancer, antitubercular and antioxidant 
agents.   
Maharan  et al., 2007[82] has synthesized series of benzothiazole-2-yl-dithiocarbamates showed 
as potent antimicrobial activity. Particularly, NH group present at second position which exhibit 
as anti-microbial, antitubercular, antioxidant and cytotoxic agents.   
Previous reported compound 
 
III-1 
Naito et al., 2002[123] has reported synthesis of [CuL(EtOH)]1-Phenyl-3- methyl-4- 
(salicyclidenehydrazide)-propylidene-5- pyrazolone as antioxidant agents. Especially, the third 
and fourth position groups may show anti-microbial, antitubercular, antioxidant and cytotoxic 
agents.   
Previous reported compound  
 
III-2 
Consequently, the combination of benzothiazole containing pyrazolone as promising approach in 
drug-like molecules design. Hence it is expected that these compounds may show antimicrobial, 
anticancer, antitubercular and antioxidant activities. 
Newly synthesized compounds  
 
 
III-3 
The aim of our work is, in connection with the above diverse biological activities we turned our 
attention to the synthesize, some newer benzothiazole containing pyrazolone bearing various 
aromatic aldehydes and related compounds, with the carefully selected auxophores like bromo, 
chloro, nitro and methoxy aldehydes groups and to facilitate biological activities of lead 
molecule by the appropriate synthetic route for anti-microbial, antitubercular, antioxidant and 
cytotoxic agents.   
 
The purpose of research was to synthesize the better activity compounds using different 
substituted aromatic aldehydes are chosen as the starting material for the synthesis of schiff’s 
bases with pyrazolone. [138] 
 
 3.1. MOLECULAR DOCKING STUDIES 
The objective of the project is to implement the grid generation and rigid docking steps of dock 
as described. Implementation of a carefully tuned form of grid calculation should be fairly easy 
to accomplish; an implementation of rigid docking will be somewhat challenging, but should 
also be possible to finish in the time allowed for the project. The grid generation implementation 
will be benchmarked using a set of target proteins ranging in size from 100 to 2000 atoms, and 
rigid docking of ligands will be benchmarked on a set of ligands ranging from 5 to 20 atoms, 
docked into a pregenerated set of 76 target points. Analysis of the limitations of the hardware for 
this problem is required, including a comparison of the different bottlenecks encountered for the 
grid generation and conformational sampling steps. Molecular docking study was on one 
tubercular protein Thymidylate Kinase of benzothiazole containing pyrazolone derivatives. [139] 
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4. PLAN OF WORK 
 
 
The plan of the present work, 
 The review of literature and scientific survey of the title compounds was done from 
1950’s.From that developed new methodology. 
 Design and docking study of designed compounds by autodock software module version 
4.0. 
 To synthesis the title Schiff base compounds, based on the reported literature procedure 
by using various aldehydes.  
 The purity of the recrystallized compounds check by melting point, TLC and solubility.  
 Characterization of synthesized compounds by various analytical techniques like UV-
Visible, FT-IR, 1H NMR and Mass spectral studies.  
 Screening of synthesized compounds for their preliminary antimicrobial activity of zone 
of inhibition by disc diffusion method, minimum inhibitory concentration by serial 
dilution method and bactericidal, fungicidal by minimum bactericidal, fungicidal 
concentration method. 
 Screening of synthesized compounds for in vitro anti-tubercular activity against 
Mycobacterium tuberculosis H37Rv by Resazurin Microplate Assay method. 
 The in vitro anti-oxidant activity of synthesized compounds to be determined by using 
DPPH, FRAP and ABTS method.  
 Screening of synthesized compounds for in vitro cytotoxic activity by MTT assay 
method. 
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5. EXPERIMENTAL WORK 
 
EXPERIMENTAL PROTOCOL 
The experimental work conducted under the following sub headings. 
EXPERIMENTAL PART I (Chapter V) 
5.1. Docking studies. 
5.2. Synthesis. 
5.2.1. Step I  Preparation of 4-nitro-1, 3-benzothiazol-2-amine. 
5.2.2. Step II  Preparation of ethyl cyano[2-(4-nitro-1,3-benzothiazol-2-yl) hyrazinylidene] 
acetate.  
5.2.3. Step III  Preparation of 5-amino-4-[2-(4-nitro-1, 3-benzothiazol-2-yl) hydrazinylidene]-2, 
4-dihydro-3H-pyrazol-3-one. 
5.2.4. Step IV  Preparation of schiff base. 
5.3. Physicochemical studies and Characterization of synthesized compounds. 
EXPERIMENTAL PART II (Chapter VI) 
6. Biological screening 
6.1. Evaluation In-vitro antimicrobial study of zone of inhibition by disc diffusion method, 
minimum inhibitory concentration by serial dilution method and bactericidal, fungicidal by 
minimum bactericidal concentration and minimum fungicidal concentration method. 
6.2. Evaluation In-vitro antitubercular activity by REMA method. 
6.3. Evaluation In-vitro antioxidant study by DPPH, FRAP, ABTS assay method. 
6.4. Evaluation In-vitro cytotoxic activity by MTTS method.  
 
5.1. DOCKING STUDIES 
5.1.1. AUTODOCK 
 
Autodock is a suite of C programs used to simulate interactions between small flexible ligands 
and macromolecules of known structure. Docking is achieved through a search of 
conformational space using a Lamarckian genetic algorithm coupled with energy assessments 
using autodock method. The combination of these two functions produces a family of molecular 
coordinates detailing possible docked ligand conformations which can then be used as a starting 
point for theoretical ligand design and study. Confidence in the docked conformation is 
represented by an energy value based on both quantum and molecular mechanical modelling of 
atomic forces. The success of a docking program depends on the Lamarckian genetic algorithm. 
[140] 
 Lamarckian genetic algorithm  
The vast majority of genetic algorithms mimics the major characteristics of darwinian evolution 
and apply mendelian genetics. This is illustrated on the one way transfer of information from the 
genotype to the phenotype. However, in those cases where an inverse mapping function exists, 
one which yields a genotype from a given phenotype, it is possible to finish a local search by 
replacing the individual with the result of the local search. This is called the Lamarckian genetic 
algorithm (LGA). The most important issues arising in hybrids of local search (LS) techniques 
with the GA revolve around the developmental mapping, which transforms genotypic 
representations into phenotypic ones. The genotypic space is defined in terms of the genetic 
operator’s mutation and cross over in our experiments by which parents of one generation are 
perturbed. The phenotypic space is defined directly by the problem, namely, the energy function 
being optimized. [141]  
In our case, the fitness or energy is calculated from the ligand’s coordinates, which together form 
its phenotype. The genotypic representations of the ligand, and its mutation and cross over 
operators, have already been described. The developmental mapping simply transforms a 
molecule’s genotypic state variables into the corresponding set of atomic coordinates. This 
means that the developmental mapping does not need to be inverted. None the less, this 
molecular variation of the genetic algorithm still qualifies as Lamarckian, because any 
‘‘environmental adaptations’’ of the ligand acquired during the local search will be inherited by 
its offspring. At each generation, it is possible to let a user defined fraction of the population 
undergo such a local search. We have found improved efficiency of docking with local search 
frequencies. [142] 
5.1.2. AUTODOCK PROCEDURE[143 ] 
Docking studies of compounds BTZP3a-BTZP3l were performed using one antimycobacterial 
protein Thymidylate Kinase (PDB ID: 1MRS) obtained from the RCSB protein data 
bank,http://www.rcsb.org/pdb.Experiments were performed using the program Autodock module 
version 4.0. 
 AutoDock includes 3 steps:  
1. Preparation of receptor & ligand files.  
2. Calculation of affinity maps by using a 3D grid around the receptor & ligand.  
3. Defining the docking parameters and running the docking simulation.  
The preparation step starts with pdb files of receptor (R.pdb) and ligand (L.pdb), which are 
added hydrogens and then saved as RH.pdb & LH.pdb. The calculation of affinity maps in the 
"Grid" section requires the above pdb files to be assigned charges & atom types, and also that the 
nonpolar hydrogens are merged. This is done automatically by ADT, and the resulting files need 
to be saved as RH.pdbqt & LH.pdbqt, which is the only format AutoGrid & AutoDock can work 
with. Calculation of affinity maps is done by AutoGrid, and then docking can be done by 
AutoDock. The newest docking algorithm is LGA (Lamarckian Genetic Algorithm).  
Preparing and Running a Docking  
1. Preparing the protein  
¾ Opening file: [Right-click "PMV molecules"] → [choose file].  
¾ Color by atom: [Click under "Atom"].  
¾ Eliminate water: Select → Select from string → [write HOH in "Residue" line 
and in the "Atom" line] → Add → Dismiss → Edit → Delete → Delete Atom 
Set.  
¾ Find missing atom and repairing them: File → Load module → [Pmv; repair 
Commands] → Edit → Misc. → Check for missing atoms → Edit → Misc. → 
Repair missing atoms.  
¾ Add hydrogen’s: Edit → Hydrogen’s → Add → [choose "All hydrogen’s", "no 
bond order", and "Yes" to renumbering].  
¾ Hide protein: [Click on the gray under "show Molecules"]. (Note: if you are 
planning rigid docking (i.e. no flexible parts in the protein), save the protein as 
RH.pdb for now)  
2. Preparing the ligand  
¾ Make sure the ligand has all hydrogens added before working with ADT. 
¾ Toggle the "AutoDock Tools" button.  
¾ Opening file: Ligand → Input → Open → All Files → [choose file] → Open. 
(ADT now automatically computes Gasteiger charges, merges nonpolar 
hydrogens, and assigns Autodock Type to each atom.)  
¾ Define torsions:  
* Ligand → Torsion Tree → Detect Root (this is the rigid part of the ligand)  
* Ligand → Torsion Tree → Choose Torsions → [either choose from the viewer 
specific bonds, or use the widget to make certain bond types active (rotatable) or 
inactive (non-rotatable). Amide bonds should NOT be active (colored pink)] → 
done.  
* Ligand → Torsion Tree → Set Number of Torsions → [choose the number of 
rotatable bonds that move the 'fewest' or 'most' atoms].  
Save ligand file:  
* Ligand → Output → Save as PDBQT → [save with L.pdbqt]. 
Hide the ligand, as explained in (A5) for the protein.  
3. Preparing the flexible residue file (Note: if you are planning rigid docking, ignore this section 
and do the following: Grid → Macromolecule → Open → [choose RH.pdb]. AutoDock will 
automatically add charges and merge hydrogens. Save the object as RH.pdbqt and move to next 
section.)  
¾ Flexible residues → Input → Choose molecule → [choose the original protein 
R.pdb] → Yes to merge nonpolar hydrogens (AutoDock assigns charges + atom 
types to R.pdb, and merges nonpolar hydrogens).  
¾ Select the residues to be flexible: Select → Select from string → ARG8 → Add 
→ Dismiss.  
¾ Define the rotatable bonds: Flexible residues → Choose torsions in currently 
selected residues → [click on rotatable bonds to inactivate them, or vice versa].  
¾ Save the flexible residues: Flexible residues → Output → Save flexible PDBQT 
→ [save as R_flex.pdbqt].   
¾ Save the rigid residues: Flexible residues → Output → Save rigid PDBQT → 
[save as R_rigid.pdbqt].  
¾ Delete this version of protein: Edit → Delete → Delete Molecule → [choose 
protein (R)] → Delete → Dismiss.  
4. Running AutoGrid calculation the purpose of this section is to define the search grid and 
produce grid maps used later by Autodock.  
¾ Open the rigid protein: Grid → Macromolecule → Open → [choose the rigid 
protein] → Yes to preserving the existing charges. (Note: if you are doing rigid 
docking, choose RH.pdbqt) 
¾ Prepare grid parameter file: Grid → Set Map Types → Choose Ligand → [choose 
the ligand already opened] → Accept. 
¾ Set grid properties: Grid → Grid Box → [Set the grid dimensions, spacing, and 
center] → File → Close Saving Current. 
¾ Save the grid settings as GPf file: Grid → Output → Save GPF → [save as 
R.gpf]. 
¾ Running: Run → Run AutoGrid → [make sure the program name has the right 
path, and that it is where the input files are] → Launch → [in the command 
prompt prompt, type "tail –f hsg1.glg" to follow the process] (Note: the AutoGrid 
calculation can be started directly from the command prompt by typing "autogrid4 
–p hsg1.gpf –l hsg1.glg ") 
 
 
5. Preparing the docking parameter file (.dpf)  
¾ Specifying the rigid molecule: Docking → Macromolecule → Set Rigid Filename 
→ [choose R_rigid.pdbqt]. (or RH.pdbqt for rigid docking)  
¾ Specifying the ligand: Docking → Ligand → Choose → [choose L.pdbqt] → 
[here you can set the initial location of the ligand] → Accept. 
¾ Specifying the flexible residues: Docking → Macromolecule → Set flexible 
Residues Filename → [choose R_flex.pdbqt]. 
¾ Setting the parameters for the chosen docking method: Docking → Search 
Parameters → Genetic Algorithm → [for 1st time, use the short number of 
evaluations (50,000), and for other runs choose the medium or long] → Accept. 5. 
Setting docking parameters: Docking → Docking Parameters → [choose the 
defaults].  
¾ Specifying the name of the ligand dpf file to be formed, containing the docking 
instructions: Docking → Output → Lamarckian GA → [type L.dpf].  
¾ Confirming the details of docking: Docking → Edit DPF → [make sure the right 
ligand pdbqt file name appears after the word "move", and that the right number 
of active torsions is specified].  
6. Running AutoDock  
¾ Make sure the AutoDock executable is in the same directory as the 
macromolecule, ligand, GPF, DPF and flex files (in case of flexible docking).  
¾ Running: Run → Run AutoDock... → Launch.  
7. When RH and LH already exist  
¾ Protein: Grid → Macromolecule → choose RH.pdb → (charges & atom types 
assigned, nonpolar hydrogen merged) → File → save → write PDBQT → save as 
RH.pdbqt  
¾ Ligand: Ligand → Input → Open → All Files → choose LH.pdb → (charges & 
atom types assigned, nonpolar hydrogen merged) → save as LH.pdbqt  
¾ Set the rest of the grid parameters & calculate map  
¾ Setting Docking parameters: Docking → Macromolecule → Set Rigid Filename 
→ choose either RH.pdbqt or RH_rigid.pdbqt → Docking → Ligand → Choose 
→ choose LH.pdbqt → set the rest of the docking parameters.  
¾ Running docking simulation.  
8. Viewing Docking Results  
A. Reading the docking log file (.dlg)  
 Analyze → Dockings → Open → [choose L.dlg].  
 Analyze → Conformations → Load → [double-click on each conformation to 
view it on screen].  
B.Visualizing docked conformations  
 Analyze → Conformations → Play... (Note: & allows changing the ligand's color) 
.The docking score and graph was given in the table 1 and Figure 1.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Table 1. Docking score of synthesized compounds 
 
Compound 
code 
Autodock (pose) score 
Kcal/mol
1MRS 
BTZP3a -6730000.0 
BTZP3b -6980000.00 
BTZP3c -5.22 
BTZP3d -5.68 
BTZP3e -6710000.0 
BTZP3f -7010000.0 
BTZP3g -5.65 
BTZP3h -5.82 
BTZP3i -6910000.0 
BTZP3j -6450000.0 
BTZP3k -5.46 
BTZP3l -5.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BTZP3h
BTZP3k
BTZP3l 
 
 
 
 
 
 
Figure 1. Docked ligand of synthesized compounds 
 
 
 
5.2. SYNTHESIS     
SCHEME 
 
 
V-1 
5.2.1. STEP 1:  SYNTHESIS OF 4-NITRO-1, 3-BENZOTHIAZOL-2-AMINE FROM   2- 
NITRO ANILINE: 
 
V-2 
PROCEDURE [144] 
To glacial acetic acid [150ml], precooled to 50c, ammonium thiocyanate [0.06mol, 4.56gm] and 
2-nitroaniline [0.06mol, 5.58gm] were added. The mixture was placed in freezing with addition 
of bromine [0.02mol, 1.01mol in 10ml glacial acetic acid] from a dropping funnel at such rate 
that temperature does not rise above 50c, stirring was continued for 5 hrs at 0-100c and 
neutralized with aqueous ammonia solution, kept it in refrigerator for overnight, filtered, washed 
with water and dried, recrystallised from ethanol to obtained 4-nitro-1, 3-benzothiazol-2-amine 
(BTZ). The solvent system used for TLC was Benzene: Methanol (9:1) and Yield: 90%w/w, 
m.p: 148˚C, Rf = 0.63. The physicochemical properties of synthesized compounds were given in 
the table 2. 
 
5.2.2. STEP 2:   SYNTHESIS OF ETHYL CYANO [2-(4-NITRO-1, 3-BENZOTHIAZOL-
2-YL) HYRAZINYLIDENE] ACETATE FROM 4-NITRO-1, 3-BENZOTHIAZOL-2-
AMINE: 
 
V-3 
 
PROCEDURE [145] 
A mixture of 4-nitro-1,3-benzothiazol-2-amine [0.02 mol, 5.8gm]  in conc.HCl [10ml in 10ml of 
water ] was cooled to 0-50c under dry ice and cooled sodium nitrite solution [1.5gm in 10ml of 
water] added to it drop wise during 10mts. The reaction mixture was then stirred for 30 mts. 
To an ice-cold mixture of ethylcyanoacetate [0.01mol, 1.13ml] and saturated solution of sodium 
acetate [0.05mol,10ml] in ethanol [50ml], was added dropwise with stirring a solution of 
diazonium salt compound over 15 mts. The stirring was continued for 30 mts at 0-50c and the 
reaction mixture then left for 1.45 hrs at room temperature. The solid product was collected and 
recrystallised from ethanol to give ethyl cyano[2-(4-Nitro-1,3-benzothiazol-2-
yl)hyrazinylidene]acetate (BTZE). The solvent system used for TLC was Benzene: Methanol 
(9:1) and Yield: 70%w/w, m.p: 122˚C, Rf = 0.74. The physicochemical properties of synthesized 
compounds were given in the table 2. 
 
5.2.3. STEP 3: SYNTHESIS OF 5-AMINO-4-[2-(4- NITRO-1,3-BENZOTHIAZOL-2-
YL)HYDRAZINYLIDENE]-2,4-DIHYDRO-3H-PYRAZOL-3-ONE FROM ETHYL 
CYANO[2-(4-NITRO-1,3-BENZOTHIAZOL-2 YL)HYRAZINYLIDENE]ACETATE : 
 
V-4 
PROCEDURE [146] 
A mixture of ethyl cyano[2-(4-Nitro-1,3-benzothiazol-2-yl)hyrazinylidene]acetate   
[0.005mol,1.64gm], hydrazines hydrate [0.01mol,0.32ml] in ethanol [30ml] was heated under 
refluxed for 4 hrs. The solvent was concentrated and the reaction product was allowed to cool. 
The separated product was filtered off, washed with water, dried and recrystallised from 
methanol to obtained 5-amino-4-[2-(4-Nitro-1,3-benzothiazol-2-yl)hydrazinylidene]-2,4-
dihydro-3H-pyrazol-3-one (BTZP) . The solvent system used for TLC was Benzene: Methanol 
(9:1) and Yield: 95%w/w, m.p: 171˚C, Rf = 0.79. The physicochemical properties of synthesized 
compounds were given in the table 2. 
 
 
 
 
 
5.2.4. STEP 4:  SYNTHESIS OF SCHIFF BASE 
 
V-5 
PROCEDURE [147] 
Mixture of 5-amino-4-[2-(4-Nitro-1,3-benzothiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-
pyrazol-3-one (0.01 mol, 1.1gm) and substituted aromatic aldehydes (0.01 mol.1.1gm)  in 
ethanol containing aceticacid (0.1mol,0.5 ml) was refluxed for 4-6 hrs. Excess of solvent was 
distilled off, concentrated and cooled. The solid thus separated was filtered, washed and 
recrystallised from ethanol. The physicochemical properties of synthesized compounds were 
given in the table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Physico chemical data of intermediate compounds 
 
 
CODE NO 
 
STRUCTURE 
 
IUPAC NAME 
 
MOLECULAR 
FORMULA  
 
 
MOL.
WT  
 
 
MP 
(OC) 
 
Rf 
value 
 
Log P 
 
 
POLARIZABILITY 
 
COLOUR 
 
% 
YIELD 
 
SOLUBILITY 
 
 
 
BTZ 
 
4-nitro-1,3-
benzothiazol-2-
amine 
C7H5N3O2S 
 
195.20 
 
148 
 
0.63 
 
1.91 18.67 Brownish 
orange 
90 
 
CHLOROFORM 
BTZE ethyl cyano[2-
(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylid
ene]acetate 
C12H9N5O4S 
 
319.30 
 
122 
 
0.74 
 
3.87 29.34 Dark red 70 
 
BENZENE  
BTZP 
 
5-amino-4-[2-
(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylid
ene]-2,4-
dihydro-3 H -
pyrazol -3-one 
C10H7N7O3S 
 
305.27 
 
171 
 
0.79 
 
1.80 27.42 Muddy 
brown 
95 
 
CHLOROFORM 
 
Solvent system:         Benzene: Methanol (9:1)                                     
Detecting agent:        Iodine vapours. 
 
 
 
 
 
Table 3. Physico chemical data of synthesized compounds 
 
 
CODE 
NO 
 
STRUCTURE 
 
IUPAC NAME 
 
MOLECULAR 
FORMULA 
 
 
MOL.
WT 
 
 
MP 
(OC) 
 
Rf 
value 
 
 
Log P 
 
POLARIZABILITY 
 
COLOUR 
 
% 
YIELD 
 
SOLUBILITY 
 
 
 
BTZP
3a 
 
4-[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
5-{[( E )-
phenylmethylidene]
amino}-2,4-dihydro-
3H -pyrazol-3-one 
C17H11N7O3S 
 
393.38 
 
107 
 
0.77 
 
4.08 38.31 Brown 90  
 
BENZENE, 
CHLOROFORM 
BTZP
3b 
 
5-({( E )-[4-
(dimethylamino)phe
nyl]methylidene}am
ino)-4-[2-(4-nitro-
1,3-benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3H- 
pyrazol-3-one 
C19H16N8O3S 
 
436.45 
 
120 
 
0.64 4.18 43.13 Brownish 
red 
94 CHLOROFORM, 
BENZENE 
BTZP
3c 
 
5-{[( E )-(3-
methoxyphenyl)met
hylidene]amino}-4-
[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3H -
pyrazol -3-one 
C18H13N7O4S 
 
423.41 
 
113 0.69 3.92 40.86 Dark 
brown 
91 BENZENE, 
CHLOROFORM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BTZP
3d 
 
5-{[( E )-(2-
chlorophenyl)methy
lidene]amino}-4-[2-
(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3H -
pyrazol -3-one 
C17H10ClN7O3S 
 
427.82 
 
112 0.40 4.68 40.25 Dark red 93 CHLOROFORM, 
BENZENE 
BTZP
3e 
 
5-{[( E )-(4-
hydroxy-3-
methoxyphenyl)met
hylidene]amino}-4-
[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3H -
pyrazol -3-one 
C18H13N7O5S 
 
439.40 
 
115 0.55 3.61 41.52 Light 
brown 
85 BENZENE, 
CHLOROFORM 
BTZP
3f 
 
4-[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
5-{[(E)-(4-
nitrophenyl)methyli
dene]amino}-2,4-
dihydro-3 H -
pyrazol -3-one 
C17H10N8O5S 
 
438.38 
 
114 0.50 4.02 40.30 Brown 88 CHLOROFORM, 
BENZENE 
 
BTZP
3g 
 
5-{[( E )-(4-
hydroxyphenyl)met
hylidene]amino}-4-
[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3 H -
pyrazol -3-one 
C17H11N7O4S 
 
409.38 
 
109 0.81 3.77 38.96 Dark red 86 BENZENE, 
CHLOROFO
RM 
BTZP
3h 
 
5-{[( E )-(4-
chlorophenyl)methy
lidene]amino}-4-[2-
(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3 H -
pyrazol -3-one 
C17H10ClN7O3S 
 
427.82 
 
111 0.52 4.68                40.24 Brownish 
orange 
87 CHLOROFO
RM, 
BENZENE 
BTZP
3i 
 
5-{[( E )-(2,4-
dihydroxyphenyl)m
ethylidene]amino}-
4-[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3 H -
pyrazol -3-one 
C17H11N7O5S 
 
425.38 
 
110 0.63 3.47 39.62 Dark 
brown 
80 CHLOROFO
RM, 
BENZENE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BTZP
3j 
 
5-{[( E )-(3,4-
dihydroxyphenyl)m
ethylidene]amino}-
4-[2-(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3 H -
pyrazol -3-one 
C17H11N7O5S 
 
425.38 
 
116 0.70 3.47 39.62 Dark red 82     BENZENE, 
CHLOROFORM 
BTZP
3k 
 
5-{[( E )-(3-
fluorophenyl)methyl
idene]amino}-4-[2-
(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3 H -
pyrazol -3-one 
C17H10FN7O3S 
 
411.37 
 
106 0.56 4.22 38.06 Brownish 
yellow 
95 CHLOROFORM, 
BENZENE 
BTZP
3l 
 
5-{[( E )-(3-
chlorophenyl)methy
lidene]amino}-4-[2-
(4-nitro-1,3-
benzothiazol-2-
yl)hydrazinylidene]-
2,4-dihydro-3 H -
pyrazol -3-one 
C17H10ClN7O3S 
 
427.82 
 
117 0.74 4.68 40.24 Brown 92 BENZENE, 
CHLOROFORM 
 
Solvent system:    Methanol: Chloroform (1:1) 
Detecting agent:  Iodine vapours.
  
5.3. PHYSICOCHEMICAL STUDIES AND CHARACTERIZATION OF SYNTHESIZED 
COMPOUNDS 
Determination of Rf values, chromatography is an important technique to identify the formation 
of synthesized compound and to determine the purity of compound. Rf value is the characteristic 
for each of the compound. 
Rf   = Distance travelled by solute / Distance travelled by solvent 
For the determination Rf value the precoated silica plate of 5cm long and 2cm width were used. 
Chromatogram were developed by ascending technique when solvent front travelled appropriate 
distance, plates were taken out and dried. The location of spot was detected by using iodine 
vapours. 
The melting points of the compounds were determined in one end fused capillary tubes on a 
THERMONIC MODEL-C-LMP-1, campbell melting point apparatus and are uncorrected. IR 
spectra were recorded in KBr pellets on JASCO FT-IR-1700 spectrometer infrared 
spectrophotometer. 1 H-NMR spetra were determined at 400 MHZ on DSX-300/AV-III 
400/DRX-500/AV-III 500(S)/ (L) AV-700 NMR spectrometer with tetramethyl silane as internal 
standard.  Mass spectra were recorded on JEOL GCmate at sophisticated instrumental analytical 
laboratory (SAIL) IIT MADRAS, Chennai. UV/Visible spectra were taken in the region of 200-
800nm, on Shimadzu UV-1700 Spectrometer. DMSO was used as a solvent. Thin layer 
Chromatography on a silicagel-G coated glass plates visualized by iodine vapours. The accurate 
weights of the chemicals were taken on the electronic balance and in analytical balance [78, 89]. 
The spectral data was given in the table 4, 5 and Figure 2, 3, 4, 5, 6, 7& 8.
  
Table 4. Spectral data of intermediate compounds 
CODE 
NO 
STRUCTURE λmax  
(nm)  
 
(IR) υmax (KBr/cm-1)  
  
1H NMR 
(DMSO, δ, ppm) 
Molecular ion 
(M+) peak 
 
 
 
BTZ  
514 3132.79(NH2 stretching) 
2936,1502.28,745.35(aromatic stretching) 
1348.32(NO2) 
1629.55(C=Nstretching) 
700(C-S-Cstretching) 
 
 
 
- 
 
 
 
- 
 
 
 
BTZE 
 
475.5 3132.79(NH stretching) 
2926,1592,749.20,(aromatic stretching) 
2856(CH stretching) 
1346.63(NO2) 
1718.26(C=Ostretching) 
1401.03(C-Nstretching) 
1624.73(C=Nstretching) 
2360.44(        stretching) 
700(C-S-Cstretching) 
1786.44(C=O of ester stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
BTZP 
 
484 3132.79(NH stretching) 
3343.05(NH2 stretching) 
2920,1597,747,(aromatic stretching) 
1340.43(NO2) 
1715.62(C=Ostretching) 
1401.03(C-N stretching) 
1618.95(C=N stretching) 
671.10(C-S-C stretching) 
6.60-8.30(m,3H,Ar proton) 
6.15 (s,1H,NH –N proton) 
3.87(s,1H,NH proton) 
8.32(s,2H,NH2  proton) 
 
 
 
 
- 
 
 
 
 
C N
  
 
 
Table 5. Spectral data of synthesized compounds 
 
CODE 
NO 
STRUCTURE λmax  
(nm)  
 
(IR) υmax  
(KBr/cm-1)  
  
1H NMR 
(DMSO, δ, ppm) 
Molecular ion 
(M+)peak 
 
 
 
BTZP
3a 
 
513 3127.97(NH stretching) 
2922.59,1572,745,(aromatic stretching) 
1344.14(NO2) 
1700.91(C=Ostretching) 
1401(C-N stretching) 
1601.59(C=N stretching) 
699.06(C-S-Cstretching) 
6.60-8.30(m,8H,Ar proton) 
6.15 (s,1H,NH-N proton) 
3.86(s,1H,NH proton) 
8.32(s,1H,N=CH proton) 
 
 
 
- 
 
 
 
BTZP
3b 
 
699 3133.76(NH stretching) 
2926,1522.52,773.31,(aromatic stretching) 
1331.61(NO2) 
1592.91(C=Ostretching) 
1401.03(C-Nstretching) 
1698.02(C=Nstretching) 
699.06(C-S-Cstretching) 
1321(N(CH3)2) 
6.62-7.69(m,7H,Ar) 
6.59(s,1H,NH-Nproton) 
3.57(s,1H,NH proton) 
8.60(s,1H,N=CH proton) 
3.04(s,6H,N(CH3)2 ) 
 
 
 
 
- 
  
 
 
 
 
 
 
 
 
  
 
 
 
BTZP
3c  
512.5 3135.69(NH stretching) 
2921.63,1524.45,756.92,(aromatic 
stretching) 
1331.61(NO2) 
1599.66(C=Ostretching) 
1401.03(C-N stretching) 
1695.12(C=Nstretching) 
697.14(C-S-C stretching) 
1070.3(C-O-C stretching) 
6.70-8.59 (m,7H,Ar) 
6.68 (s,1H,NH-N proton ) 
3.88(s,1H,NH proton) 
8.64 (s,1H,N=CH proton)  
3.35(s,3H,(OCH3) 
 
 
 
 
- 
 
 
 
 
BTZP
3d 
 
455 3128.94(NH stretching) 
2962,1509.99,772.36,(aromatic stretching) 
1311.36(NO2) 
1596.77(C=O stretching) 
1400.07(C-N stretching) 
1679.69(C=Nstretching) 
699.06(C-S-C stretching) 
830.20(C-Cl) 
6.32-8.30(m,7H,Ar) 
6.15(s,1H,NH-N proton) 
3.89(s,1H,NH proton) 
8.32 (s,1H,N=CH proton) 
 
 
 
 
- 
 
 
 
BTZP
3e 
 
479 3127.01(NH stretching) 
2960,1512.88,733.78,(aromatic stretching) 
1348.18(NO2) 
1623.77(C=O stretching)  
1401.03(C-N stretching) 
1686.44(C=Nstretching) 
696(C-S-C stretching) 
1081.62(C-O-C stretching) 
3373(OH stretching) 
7.39-8.33(m,6H,Ar) 
7.36 (s,1H,NH-N proton) 
3.89(s,1H,NH proton) 
8.85 (s,1H,N=CH proton) 
3.34(s,3H,(OCH3) 
9.87(s,1H,OH) 
 
 
 
 
     - 
 
 
 
BTZP
3f 
 
512.5 3127.01(NH stretching) 
2960,733.78,(aromatic stretching) 
1512.88,1348.18(NO2) 
1623.77(C=O stretching)  
1401.03(C-N stretching) 
1686.44(C=Nstretching) 
696(C-S-C stretching) 
6.60- 8.21(m,7H,Ar) 
6.15 (s,1H,NH-N proton)  
3.89 (s,1H,NH proton)  
8.23 (s,1H,N=CH proton) 
 
 
 
     - 
 
 
 
  
 
 
 
 
 
BTZP
3g 
 
514 3133.79(NH stretching) 
2932,1502.28,745.35,(aromatic stretching) 
1348.72(NO2) 
1602.28(C=O stretching)  
1401.03(C-N stretching) 
1629.55(C=Nstretching) 
686(C-S-C stretching) 
3378.67(OH stretching) 
6.94-7.76(m,7H,Ar) 
6.92(s,1H,NH-N proton) 
3.86(s,1H,NH proton) 
7.77(s,1H,N=CH proton)  
9.79(s,1H,OH) 
 
 
409.38 
 
 
 
 
 
 
BTZP
3h 
 
401 3141.47(NH stretching) 
2920,1492.63,740.53(aromatic stretching) 
1339.36(NO2) 
1573.63(C=Ostretching) 
1401.03(C-N stretching) 
1681.62(C=N stretching) 
686(C-S-C stretching) 
821(C-Cl) 
6.61-8.25(m,7H,Ar) 
6.60(s,1H,NH-N proton) 
3.86(s,1H,NH proton)  
8.31(s,1H,N=CH proton)  
 
 
 
 
- 
 
 
 
BTZP
3i 
 
511 3152.08(NH stretching) 
2921.63,1501.34,740.53(aromatic stretching) 
1337.5(NO2) 
1699(C=O stretching) 
1400.03(C-N stretching) 
1622.84(C=N stretching) 
780(C-S-C stretching) 
3433.62,3364.21(OH stretching) 
6.60-8.30(m,6H,Ar) 
6.15(s,1H,NH-N proton) 
3.86(s,1H,NH proton) 
8.32(s,1H,N=CH proton)  
9.87(s,2H,OH) 
 
 
 
 
- 
 
 
 
 
 
 
 
 
  
 
 
 
BTZP
3j 
 
514 3151.11(NH stretching) 
2920,1502,742.46,(aromatic stretching) 
1333.57(NO2) 
1623.77(C=O stretching) 
1401.03(C-N stretching) 
1677.77(C=N stretching) 
686(C-S-C stretching) 
3463.2,3378.67(OH stretching) 
6.60-7.39(m,6H,Ar) 
6.15(s,1H,NH-N proton) 
3.86(s,1H,NH proton)  
7.40(s,1H,N=CH proton) 
9.87(s,2H,OH) 
 
 
 
 
- 
 
 
 
BTZP
3k 
 
513 3160.75(NH stretching) 
2920,1588,733.17,(aromatic stretching) 
1336.32(NO2) 
1598.7(C=O stretching) 
1400.07(C-N stretching) 
1676.8(C=N stretching) 
603.6(C-S-C stretching) 
1416(C-F strecting) 
6.68-8.59(m,7H,Ar) 
6.15(s,1H,NH-N proton) 
3.87(s,1H,NH proton) 
8.64(s,1H,N=CH proton)  
 
 
 
 
411.37 
 
 
 
 
 
BTZP
3l 
 
477.5 3149.19(NH stretching) 
2920,1494.91,737,(aromatic stretching) 
1343.03(NO2) 
1590.02(C=O stretching) 
1401.03(C-N stretching) 
1675.84(C=N stretching) 
686(C-S-C stretching) 
837.19(C-Cl) 
7.02-7.95(m,7H,Ar) 
7.00(s,1H,NH-N proton) 
3.86(s,1H,NH proton) 
7.96(s,1H,N=CH proton)  
 
 
 
 
 
- 
 
  
Figure 2. UV-Visible spectra of intermediate compounds 
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Figure 3. UV-Visible spectra of synthesized compounds 
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Figure 4. IR Spectra of intermediate compounds 
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Figure 6. NMR spectra of intermediate compounds 
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Figure 7. NMR spectra of synthesized compounds 
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Figure 8. Mass spectra of synthesized compounds 
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6. BIOLOGICAL SCREENING 
 
 
6.1. Evaluation In vitro antimicrobial study of zone of inhibition by disc diffusion 
method, minimum inhibitory concentration by serial dilution method and bactericidal, 
fungicidal by minimum bactericidal concentration and minimum fungicidal concentration 
method. 
6.2. Evaluation In vitro antitubercular activity by REMA method. 
6.3. Evaluation In vitro antioxidant study by DPPH, FRAP, ABTS assay method. 
            6.4. Evaluation In vitro cytotoxic activity by MTTS method.  
 
6.1. ANTIMICROBIAL STUDIES 
Antimicrobial testing is indicated for any organism that contributes to an infectious disease 
warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from 
pre-existing antibiograms. The introduction of a variety of antimicrobials today makes it a 
necessity to perform the antimicrobial susceptibility test, the results of which can guide us to the 
selection of appropriate antimicrobial drug with unquestionable benefit and least problem of 
antimicrobial resistance. Two methods were used for the antimicrobial studies. 
 Zone of inhibition (Disc diffusion method) 
 Minimum inhibitory concentration (Serial dilution method) 
6.1.1. DISC DIFFUSION METHOD 
Principle 
When a filter paper disc impregnated with a chemical is placed medium containing agar, the 
chemical will diffuse from the disc into the agar. This diffusion places the chemical in the agar 
around the disc. The area of chemical infiltration around the disc is determined by the solubility 
of the chemical and its molecular size. An organism placed on the agar fails to grow in the area 
around the disc if it is susceptible to the chemical. This area of around the disc where no growth 
is observed is known as a “zone of inhibition”. 
The drug potency is established by comparing the inhibition produced by the test compound with 
that produced by known concentration of reference standard. When performing these tests 
certain things are held constant so only the size of the zone of inhibition is variable. Conditions 
  
that must be constant from test to test include the agar used, the amount of organism used, the 
concentration of chemical used, and incubation conditions (time, temperature, and atmosphere). 
6.1.2. ANTIBACTERIAL SCREENING BY DISC DIFFUSION METHOD 
The antibacterial activities of synthesized compounds were screened in the concentration of 1 
µg/µl in dimethyl sulphoxide (DMSO) against the listed microorganisms, obtained from National 
Collection of Industrial Microorganisms (NCIM), Pune and Microbial Type Culture Collection 
(MTCC), Chandigarh, in the Muller Hinton agar medium by disc diffusion method using 
ciprofloxacin (0.5 µg/µl) as standard. The antibacterial activity was evaluated by measuring zone 
of inhibition in mm. 
Table 6. List of bacterial strains used in the study 
GRAM POSITIVE GRAM NEGATIVE 
Micrococcus luteus MTCC 2169 Escherichia coli MTCC 2065 
Staphylococcus aureus MTCC 2079 Pseudomonas aruginosa MTCC 2200 
Bacillus subtills MTCC 2063 Rhodosporum ruberum MTCC 5128 
Corney bacterium MTCC 2640 Viberio cholera MTCC 1738 
Bacillus lintus NCIM 2018 Salmonella Paratypic NCIM 2501 
Staphylococcus albus MTCC 2178 Klebsiella pneumoniae NCIM 2707 
 
Preparation of inoculums 
Preparation of inoculums of bacteria was carried out by Muller Hinton Broth and transferred to 
test tube and kept it for sterilization in autoclave at 1200 C for 15 min. Then added culture of 
each bacterium to each tube (this step was carried out in aseptic room near laminar air flow) then 
kept it for incubation in incubator for 18-24 h at 370 C. 
Procedure 
Muller Hinton agar medium was prepared by dissolving 21 gm of Muller Hinton agar in 1000 ml 
of distilled water and agar-agar 1-2 gm for solublization. Then kept it for sterilization in 
autoclave for 1210 C for 15 min. The petri plates were cleaned, sterilized and marked. These 
medium (Muller Hinton agar) were poured into petri-plates under aseptic conditions and allowed 
to solidify. Standardized bacterial inoculum was spread uniformly over the surface of medium by 
using a sterile non-absorbent cotton swab and finally the swab was passed around the edge of the 
  
medium. The inoculated petri plates were closed with the lid and allowed to dry at room 
temperature. The sample impregnated discs and standard discs were placed on the inoculated 
agar medium. All petriplates were incubated at 370C for 24 h. After the incubation, diameter of 
zone of inhibition produced by the sample and standard was measured. The details are tabulated 
in Table 8, 9 and Figure 9, 10, 11 and 12. 
 
6.1.3. ANTIFUNGAL SCREENING BY DISC DIFFUSION METHOD 
The antifungal activities of synthesized compounds were screened in the concentration of 1µg/µl 
in dimethyl sulphoxide (DMSO) against the listed fungal strains, obtained from National 
Collection of Industrial Microorganisms (NCIM), Pune and Microbial Type Culture Collection 
(MTCC), Chandigarh, in the Sabourand’s Dextrose Broth by disc diffusion method using  
Clotrimazole (10 µg disc) as standard. The antifungal activity was evaluated by measuring zone 
of inhibition in mm. 
 
Table 7. List of fungal strains used in the study 
Candida albicans MTCC 3100 
Monococcus purpureus MTCC 1090 
Aspergillus niger MTCC 1344 
Trichophyton rubrum MTCC 3272 
Aspergillus fumigates MTCC 1811 
Aspergillus parasites MTCC 2796 
 
Preparation of inoculums 
Preparation of inoculums of fungus was carried out by Sabourand’s Dextrose Broth and 
transferred to test tube and kept it for sterilization in autoclave at 1200 C for 15 min. Then added 
culture of each fungal to each tube (this step was carried out in aseptic room near laminar air 
flow) then kept it for incubation in incubator for 24-48 h at 290 C. 
 
Procedure 
Sabourand’s Dextrose agar medium was prepared by dissolving 1 gm of peptone and 4 gm of 
dextrose in 100 ml of distilled water and agar-agar 1-2 gm for solublization. Then kept it for 
  
sterilization in autoclave for 1210 C for 15 min. The petri plates were cleaned, sterilized and 
marked. These medium (Sabourand’s Dextrose agar) were poured into petri-plates under aseptic 
conditions and allowed to solidify. Standardized fungal inoculum was spread uniformly over the 
surface of medium by using a sterile non-absorbent cotton swab and finally the swab was passed 
around the edge of the medium. The inoculated petri plates were closed with the lid and allowed 
to dry at room temperature. The sample impregnated discs and standard discs were placed on the 
inoculated agar medium. All petriplates were incubated at 290C for 24 - 48 h. After the 
incubation, diameter of zone of inhibition produced by the sample and standard was 
measured.[148] The details are tabulated in Table 10 and Figure 13, 14. 
 
6.1.4. SERIAL DILUTION METHOD 
Principle 
Minimum inhibitory concentration (MIC), in microbiology, is the lowest concentration of an 
antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. 
Dilution tests are used to determine the MIC of an agent required to inhibit or kill the 
microorganism. This can be achieved by dilution of antimicrobial agent in either agar or broth 
media. The potency of drug is based on inhibition of microbial growth as indicated by 
measurement of turbidity of a suspension of a suitable microorganism in a fluid medium to 
which graded amount of test compound have been added. The changes in turbidity produced by 
known concentration of reference materials are compared with the results. 
6.1.5. MIC STUDIES 
Procedure for determination of minimum inhibitory concentration for synthesized 
compounds against bacteria by serial dilution method 
The serial dilution of compound solutions were made from the stock (1000 µg/ml) by using 
Muller Hinton broth using the method described below. 
 The tubes were labeled 1 to 8 and 1 ml of Muller Hinton broth was added to the first 5 
tubes and 8th tube, and then added 0.5 ml Muller Hinton broth to 6th and 7th tubes. 
 One ml of different synthesized compounds was added to the 1st tube, mixed and 
transferred 1 ml serially up to tube 6. Mixed and transferred 0.5 ml to the 7th tube so that 
each tube, 1 to 7 contained 1 ml diluted extracts. The 8th tube served as the control. 
  
 With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01 ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 37 0 C for 18 h. 
 After incubation the turbidity was observed. The highest dilution of particular compounds 
showing no turbidity and recorded. This was taken as the end point, and this dilution was 
considered to contain the concentration of drug equivalent to MIC [149]. The details are 
tabulated in Table11, 12 and Figure 15, 16. 
 
Procedure for determination of minimum inhibitory concentration for synthesized 
compounds against fungi by serial dilution method 
The serial dilution of compound solutions were made from the stock (1000 µg/ml) by using 
Sabourand’s dextrose broth using the method described below. 
 The tubes were labeled 1 to 8 and 1 ml of Sabourand’s dextrose broth was added to the 
first 5 tubes and 8th tube, and then added 0.5 ml Muller Hinton broth to 6th and 7th 
tubes. 
 One ml of different synthesized compounds was added to the 1st tube, mixed and 
transferred 1 ml serially up to tube 6. Mixed and transferred 0.5 ml to the 7th tube so that 
each tube, 1 to 7 contained 1 ml diluted extracts. The 8th tube served as the control. 
 With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 270 C for 24 - 48 h. 
 The highest dilution of particular compounds showing no turbidity was observed and 
recorded. This was taken as the end point, and this dilution was considered to contain the 
concentration of drug equivalent to MIC. [150]  The details are tabulated in Table 13 and 
Figure 17. 
 
6.1.6. BACTERICIDAL/FUNGICIDAL 
Principle 
Minimum bactericidal concentration (MBC) and Minimum fungicidal concentration (MFC), in 
microbiology, is the lowest concentration of an antimicrobial that will inhibit the visible growth 
of a microorganism after overnight incubation. Dilution tests are used to determine the MBC, 
  
MFC of an agent required to inhibit or kill the microorganism. This can be achieved by dilution 
of antimicrobial agent in either agar or broth media.  
⇒ Bactericidal and fungicidal agents are those which are able to kill bacteria and fungi. 
⇒ Bacteriostatic and fungiostatic agents are those which are able to prevent the 
multiplication of bacteria and fungi. 
⇒ A chemical agents which is bactericidal and fungicidal at a particular concentration, may 
only the bacteriostatic and fungiostatic agents at a higher dilution. 
Procedure for determination of minimum bactericidal concentration (MBC) 
Procedure 
Muller Hinton agar medium was prepared by dissolving 21 gm of Muller Hinton agar in 1000 ml 
of distilled water and agar-agar 1-2 gm for solublization. Then kept it for sterilization in 
autoclave for 1210 C for 15 min. The petri plates were cleaned, sterilized and marked. These 
medium (Muller Hinton agar) were poured in the sterile petri plates to this add 100µl of muller 
hinton broth from the MIC tube (after determining Minimum inhibitory concentration (MIC) 
value) and mixed well, allowed to solidify. Three more petri plates also prepared from the MIC 
tube with high concentration. The petri plates were closed with the lid and allowed to dry at 
room temperature. All petri plates were allowed to incubation at370C for 24 hrs. The minimum 
bactericidal concentration (MBC) were determined by sub culturing 100 μL of culture from each 
tube that remained clear in the MIC determination into fresh medium. MBC values represent the 
lowest concentration of compound that produces a 99.9% end point reduction. [151]     
Procedure for determination of minimum fungicidal concentration (MFC) 
Procedure 
Sabourand’s Dextrose agar medium was prepared by dissolving 1 gm of peptone and 4 gm of 
dextrose in 100 ml of distilled water and agar-agar 1-2 gm for solublization. Then kept it for 
sterilization in autoclave for 1210 C for 15 min. The petri plates were cleaned, sterilized and 
marked. These medium (Sabourand’s Dextrose agar) were poured in the sterile petri plates to this 
add 100µl of sabourand’s dextrose broth from the MIC tube (after determining Minimum 
inhibitory concentration (MIC) value)  and mixed well, allowed to solidify. Four more petri 
plates also prepared from the MIC tube with high concentration. The petri plates were closed 
with the lid and allowed to dry at room temperature. All petri plates were allowed to incubation 
at290C for 48 hrs.The minimum fungicidal concentration (MFC) were determined by sub 
  
culturing 100 μL of culture from each tube that remained clear in the MIC determination into 
fresh medium.MFC values represent the lowest concentration of compound that produces a 
99.9% end point reduction. [151]     
 
 
ANTIMICROBIAL STUDIES 
Table 8.  Antibacterial screening of synthesized compounds (gram positive strains) by disc 
diffusion method 
Compound  
code 
Mean zone of inhibition (in mm) and percentage inhibition 
Micrococc
us Luteus  
Staphylococcus 
Aureus 
Bacillus 
Substils 
Corney 
Bacterium 
Bacillus 
Lintus 
Staphylococcus 
Albus 
BTZP3a 10 (83%) 11 (73%) 9 (60%) 9 (60%) 12 (80%) 9 (60%) 
BTZP3b 9 (75%) 9 (60%) 9 (60%) 11 (73%) 12 (80%) 9 (60%) 
BTZP3c 9 (75%) 11 (73%) 11 (73%) 10 (66%) 12 (80%) 10 (66%) 
BTZP3d 10 (83%) 10 (66%) 11 (73%) 10 (66%) 12 (80%) 10 (66%) 
BTZP3e 9 (75%) 9 (60%) 9 (60%) 9 (60%) 11 (73%) 9 (60% ) 
BTZP3f 9 (75%) 9 (60%) 9 (60%) 11 (73%) 11 (73%) 9 (60%) 
BTZP3g 10 (83%) 9 (60%) 10 (66%) 11 (73%) 13 (86%) 11 (73%) 
BTZP3h 10 (83%) 9 (60%) 10 (66%) 9 (60%) 13 (86%) 11 (73%) 
BTZP3i 9 (75%) 10 (66%) 10 (66%) 10 (66%) 11 (73%) 11 (73%) 
BTZP3j 9 (75%) 9 (60%) 11 (73%) 9 (60%) 11 (73%) 10 (66%) 
BTZP3k 9 (75%) 11 (73%) 9 (60%) 10 (66%) 11 (73%) 9 (60%) 
BTZP3l 9 (75%) 11 (73%) 9 (60%) 10 (66%) 10 (66%) 9 (60%) 
Ciprofloxacin 12 15 15 15 15 15 
 
BTZP3a-l          =    Synthesized compounds in the concentration of 100 µg/disc. 
Standard       =   Ciprofloxacin in the concentration of 5 µg/disc. 
Solvent          =   DMSO. 
Media            =   Bacteria:   Muller Hinton Agar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 9. Antibacterial screening of synthesized compounds (gram positive strains) by disc 
diffusion method 
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Table 9.  Antibacterial screening of synthesized compounds (gram negative bacteria) 
 By disc diffusion method 
 
Compound 
code 
Mean zone of inhibition (in mm) and percentage inhibition 
Escherichia 
Coli 
Pseudomonas 
Aruginosa 
Rhodosporum 
Ruberum 
Viberio 
Cholera 
Salmonella 
Paratyphii 
Klebsiella 
Pneumoniae 
BTZP3a 9 (56%)   8 (62%)     8 (80%) 10 (45%) 10 (125%) 10 (111%) 
BTZP3b 10 (62%) 8 (62%) 11 (110%) 10 (45%) 13 (162%) 10 (111%) 
BTZP3c 11 (68%) 8 (62%)     8 (80%) 10 (45%) 13 (162%) 10 (111%) 
BTZP3d 10 (62%) 8 (62%)    10 (100%) 13 (59%) 14 (175%) 12 (133%) 
BTZP3e 9 (56%) 8 (62%)     9 (90%) 13 (59%) 12 (150%) 11 (122%) 
BTZP3f 10 (62%) 8 (62%) 10 (100%) 13 (59%) 12 (150%) 11 (122%) 
BTZP3g 10 (62%) 8 (62%) 11 (110%) 13 (59%) 10 (125%) 11 (122%) 
BTZP3h 9 (56%) 11 (85%) 10 (100%) 13 (59%) 13 (162%)   14(155%) 
BTZP3i 10 (62%) 8 (62%) 9 (90%) 13 (59%) 13 (162%)   13(144%) 
BTZP3j 8 (50%) 11 (85%) 8 (80%) 13 (59%) 13 (162%) 11 (122%) 
BTZP3k 8 (50%) 9 (69%) 8 (80%) 13 (59%) 10 (125%) 10 (111%) 
BTZP3l 8 (50%) 9 (69%) 8 (80%) 13 (59%) 10 (125%) 10 (111%) 
Ciprofloxacin 16 13 10 22 8 9 
 
BTZP3a-l       =   Synthesized compounds in the concentration of 100 µg/disc. 
Standard      =   Ciprofloxacin in the concentration of 5 µg/disc. 
Solvent         =   DMSO. 
Media          =   Bacteria   :     Muller Hinton Agar.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
igure 11.  Antibacterial screening of synthesized compounds (gram negative strains) by disc 
diffusion method 
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Table 10. Antifungal screening of synthesized compounds (fungi strains) by disc 
diffusion method 
Compound 
code 
  Mean zone of inhibition (in mm) and percentage inhibition 
Candida 
Albicans 
Monococcus 
Purpureus 
Aspergillus 
Niger 
Trichophyton 
rubrum 
Aspergillus 
Fumigates 
Aspergillus 
Parasites 
BTZP3a 9 (75%) 9 (82%) 10 (77%) 11 (85%) 8 (80%) 13 (130%) 
BTZP3b 9 (75%) 9 (82%) 10 (77%) 9 (69%) 8 (80%) 9 (90%) 
BTZP3c 11 (91%) 9 (82%) 10 (77%) 9 (69%) 8 (80%) 9 (90%) 
BTZP3d 9 (75%) 9 (82%) 11 (85%) 9 (69%) 13 (130%) 8 (80%) 
BTZP3e 11 (91%) 9 (82%) 10 (77%) 9 (69%) 11 (110%) 8 (80%) 
BTZP3f 12 (100%) 9 (82%) 13 (100%) 9 (69%) 8 (80%) 8 (80%) 
BTZP3g 13 (108%) 14 (127%) 13 (100%) 13 (100%) 10 (100%) 9 (90%) 
BTZP3h 11 (91%) 14 (127%) 13 (100%) 13 (100%) 10 (100%) 11 (110%) 
BTZP3i 9 (75%) 14 (127%) 10 (77%) 11 (85%) 8 (80%) 9 (90%) 
BTZP3j 11(91%) 9 (82%) 13 (100%) 13 (100%) 8 (80%) 9 (90%) 
BTZP3k 13 (108%) 14 (127%) 11 (85%) 9 (69%) 8 (80%) 8 (80%) 
BTZP3l 11 (91%) 14 (127%) 10 (77%) 9 (69%) 8 (80%) 8 (80%) 
Clo-
trimazole 
12 11 13 13 10 10 
 
 
BTZP3a-l      =   Synthesized compounds in the concentration of 100 µg/disc. 
Standard      =   Clotrimazole in the concentration of 5 µg/disc 
Solvent         =   DMSO. 
Media           =   Fungi       :     Sabourand’s Dextrose Agar.    
 
 
   
 
 
 
Figure  13.  Antifungal screening of synthesized compounds at 100µg/discs by disc diffusion 
method 
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Table 11. Minimum inhibitory concentration of synthesized compounds (gram positive 
strains) by serial dilution method 
Compound 
code 
Minimum inhibitory concentration (in microgram/ml) 
Micrococcus 
Luteus 
Staphylococcus 
Aureus 
Bacillus 
Substils 
Corney 
Bacterium  
Bacillus 
Lintus 
Staphylococcus 
Albus 
  BTZP3a 12.5 12.5 25 25 6.25 25 
  BTZP3b 25 25 25 12.5 12.5 25 
  BTZP3c 25 12.5 12.5 25 12.5 25 
  BTZP3d 12.5 25 12.5 25 6.25 25 
  BTZP3e  25 25 25 25 25 25 
  BTZP3f 25 25 25 12.5 25 25 
  BTZP3g 12.5 25 25 12.5 6.25 12.5 
  BTZP3h  12.5 25 25 25 6.25 12.5 
  BTZP3i 25 25 25 25 25 12.5 
  BTZP3j 25 25 12.5 25 25 25 
  BTZP3k 25 12.5 25 25 25 25 
  BTZP3l 25 12.5 25 25 25 25 
Ciprofloxacin 1.56 1.56 1.56 1.56 1.56 1.56 
 
BTZP3a-l      =   Synthesized compounds in the concentration of 100-1.56 µg/ml. 
Solvent         =    DMSO.  
Media          =    Bacteria   :     Muller Hinton Broth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Table 12. Minimum inhibitory concentration of synthesized compounds (gram negative 
strains) by serial dilution method 
Compound 
code 
Minimum inhibitory concentration(in microgram/ml) 
Escherichia 
Coli 
Pseudomonas 
Aruginosa 
Rhodosporum 
Ruberum 
Viberio 
Cholera 
Salmonella 
Paratyphii 
Klebsiella 
Pneumoniae 
  BTZP3a 25 25 12.5 25 25 25 
  BTZP3b 25 25 1.56 25 6.25 25 
  BTZP3c 25 25 12.5 25 6.25 25 
  BTZP3d 25 25 3.12 25 3.12 6.25 
  BTZP3e  25 25 6.25 25 12.5 12.5 
  BTZP3f 25 25 3.12 25 12.5 12.5 
  BTZP3g 25 25 3.12 25 25 12.5 
  BTZP3h  25 12.5 3.12 25 6.25 3.12 
  BTZP3i 25 25 6.25 25 6.25 3.12 
  BTZP3j 25 12.5 12.5 25 6.25 12.5 
  BTZP3k 25 25 12.5 25 25 25 
  BTZP3l 25 25 12.5 25 25 25 
Ciprofloxacin 1.56 1.56 1.56 1.56 1.56 1.56 
  
BTZP3a-l      =    Synthesized compounds in the concentration of 100-1.56 µg/ ml. 
Solvent         =     DMSO. 
Media           =    Bacteria   :     Muller Hinton Broth.  
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Table 13. Minimum inhibitory concentration of synthesized compounds (fungi strains)   by 
serial dilution method 
Compound 
code 
  Minimum inhibitory concentration(in microgram/ml) 
Candida 
Albicans 
Monococcus 
Purpureus 
Aspergillus 
Niger 
T.Rubrum Aspergillus 
Fumigates 
Aspergillus 
Parasites 
BTZP3a 25 6.25 25 12.5 12.5 3.12 
BTZP3b 25 6.25 25 25 12.5 6.25 
BTZP3c 12.5 6.25 25 25 12.5 6.25 
BTZP3d 25 6.25 12.5 25 3.12 12.5 
BTZP3e 12.5 6.25 12.5 25 3.12 12.5 
BTZP3f 6.25 6.25 6.25 25 12.5 12.5 
BTZP3g 3.12 3.12 6.25 3.12 6.25 6.25 
BTZP3h 12.5 3.12 6.25 3.12 6.25 3.12 
BTZP3i 25 3.12 12.5 12.5 12.5 6.25 
BTZP3j 12.5 6.25 6.25 3.12 12.5 6.25 
BTZP3k 3.12 3.12 12.5 25 12.5 12.5 
BTZP3l 12.5 3.12 12.5 25 12.5 12.5 
Clo-
trimazole 
1.56 1.56 1.56 1.56 1.56 1.56 
 
BTZP3a-l      =   Synthesized compounds in the concentration of 100-1.56 µg/ ml. 
Solvent         =   DMSO. 
Media           =   Fungi       :     Sabourand’s Dextrose Broth.                         
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 15. Minimum inhibitory concentration of synthesized compounds (gram positive 
strains) by serial dilution method 
         
 
Figure 16. Minimum inhibitory concentration of synthesized compounds (gram negative 
strains) by serial dilution method 
      
 
Figure 17. Minimum inhibitory concentration of synthesized compounds (fungal strains)   
by serial dilution method 
     
 
 
 
                     
 
 
 
 
 
 
 
 
   
 
6.2. ANTITUBERCULAR SCREENING 
The slow growth of Mycobacterium tuberculosis, M. avium, and related species and longer 
incubation times limits the use of drug susceptibility assays which rely on the development of 
colonies or turbidity for antitubercular screening. Susceptibility can be determined more rapidly 
with the radiometric BACTEC 460 system, the clinical drug susceptibility system of choice for 
most of the last decade, but it has the disadvantages of high cost, high volume, lack of high-
throughput format, and requirement for radioisotope disposal. 
6.2.1. RESAZURIN MICROPLATE ASSAY 
Principle  
Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) is a blue dye, itself nonfluorescent until 
it is reduced to the pink colored and highly red fluorescent resorufin by oxidoreductases within 
viable cells.  It is used mainly as an oxidation-reduction indicator in cell viability assays for 
bacteria and mammalian cells, the principle being that resazurin does not fluoresce when 
exposed to green light while resorufin fluoresces. 
 
Procedure 
The anti-TB activity of the compounds was tested by resazurin microplate assay. M. tuberculosis 
H37Rv was grown in Middlebrook 7H9 broth (Difco BBL, Sparks, MD, USA) supplemented 
with 10 % OADC (Becton Dickinson, Sparks, MD, USA) and 0.5% glycerol. The optical density 
of the bacterial culture was adjusted to McFarland 1.0 unit and 50 µl from this suspension was 
used as the inoculums. Stock solutions of the test compounds were prepared in dimethyl 
formamide (DMF) and were added to fresh medium in the wells of a 96-well microplate to which 
50 µl inoculum was added making the total assay volume 200 µl. The final concentrations of the 
test molecules were 1, 10 and 100 µg/ml. Growth control wells contained medium and M. 
tuberculosis H37Rv alone. Rifampicin (1.0 µg/ml) served as positive control for inhibition of 
growth. Negative control wells contained the highest volume of DMF used in test wells without 
any compound. After incubation at 37ºC for 7 days, 15 µl of 0.01% resazurin (Sigma, St. Louis. 
MO, USA) solution in sterile water was added to the first growth control wells and incubated for 
24 h. Once the first set of growth controls turned pink, the dye solution was added to the second 
set of growth controls and the test wells, and incubated for 24 h at 37ºC. Blue color in the wells 
   
 
containing the test compounds indicated inhibition of growth and pink indicated lack of 
inhibition of growth of M. tuberculosis. [152] The details are tabulated in Table14 and Figure 18. 
 
IN VITRO ANTITUBERCULAR STUDIES 
Table 14. Invitro antitubercular screening by REMA method 
Compound 
code 
Concentration (μg /ml) 
 
1 10 100 
 
BTZP3g N N P 
 
BTZP3h N P P 
 
BTZP3i N P P 
 
BTZP3j N N P 
 
BTZP3k N P P 
 
BTZP3l N P P 
Control N N 
 
Rifampicin P P 
  
      N = No inhibition  
      P = Inhibition  
 
Reagents used  
         Reagents              :        Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide.  
       Concentration       :        1, 10 and 100 µg/ml.  
       Standard               :        Rifampicin  
        Media                   :        Middlebrook 7H9 broth.  
        Solvent                 :        DMF.  
 
 
 
 
 
 
 
   
 
 
 
 
  
Figure 18. Invitro antitubercular screening by REMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
6.3. IN VITRO ANTIOXIDANT STUDIES 
 
An antioxidant is the one capable of slowing or preventing the oxidation where it protects the 
cell damage by reactive oxygen species that are produced during redox reactions in the cell. 
Antioxidants found in the body can be small molecules such as glutathione, vitamins, or 
macromolecules such as catalase, glutathione peroxidase. As oxidative stress contributes to the 
development of many diseases including Alzheimer's disease, Parkinson's disease, diabetes, 
rheumatoid arthritis and neurodegeneration, the use of antioxidants in pharmacology is 
intensively studied. The antioxidant assays can roughly be classified into two types: 
 Assays based on hydrogen atom transfer (HAT) reactions 
The majority of HAT-based assays apply a competitive reaction scheme, in which antioxidant 
and substrate compete for thermally generated peroxyl radicals through the decomposition of azo 
compounds. Some examples of such assays include inhibition of induced low-density lipoprotein 
autoxidation, oxygen radical absorbance capacity (ORAC), total radical trapping antioxidant 
parameter (TRAP) and crocin bleaching assays. 
 Assays based on electron transfer (ET) 
These assays measure the capacity of an antioxidant in the reduction of an oxidant, which 
changes color when reduced. The sample's antioxidant concentration is correlated with the 
degree of its color change. Examples of such assays include the total phenols assay by Folin-
Ciocalteu reagent (FCR), Trolox equivalence antioxidant capacity (TEAC), ferric ion reducing 
antioxidant power (FRAP), "total antioxidant potential" assay using a Cu(II) complex as an 
oxidant and DPPH radical scavenging assay.In addition, there are also other assays intended to 
measure a sample's scavenging capacity of biologically relevant oxidants such as singlet oxygen, 
superoxide anion, peroxynitrite etc.[153] In-vitro Anti-oxidant screening of synthesized 
compounds were done by using three methods 
 DPPH method 
 FRAP method and 
 ABTS method 
 
 
 
   
 
6.3.1. DPPH RADICAL SCAVENGING METHOD 
The free radical scavenging activity of a compound determined by this method is based on a 
reaction between a chomogen compound and antioxidant, and the concentration of the chomogen 
which is unreacted determined spectrophotometrically or colorimetrically. Most often used 
chomogen compound is DPPH (2, 2-Diphenyl-1-Picryl-hydrazyl). 
Principle 
DPPH molecule is characterized as a stable free radical by virtue of delocalization of the 
unpaired electron which gives rise to the deep violet colour, characterized by an absorption at 
about 518 nm.When solution of DPPH mixed with that of a substance that can donate a hydrogen 
atom (ie an antioxidant) it is converted to its reduced form with the loss of this violet color to 
pale yellow color. The primary reaction involved in this assay is given below 
Z. +AH=ZH+A. 
 Where, 
Z.     = DPPH radical  
AH   = Donor molecule 
ZH   = Reduced form 
A.    = Free radical 
The result of the antioxidant efficiency is expressed as EC50, determined as the concentration of 
substrate that causes 50% loss in absorbance. 
Reagents used 
Radical        :      DDPH 
Solvent        :      Ethanol 
Standard      :      Ascorbic acid 
Preparation of 0.3 mM DPPH  solution: 
It was prepared by dissolving DPPH (5.91 mg) in 50 ml of ethanol. This stock solution was 
prepared freshly and kept in the dark at ambient temperature when not used. 
Preparation of sample stock solution: 
The sample stock solution was prepared by dissolving the compound in suitable solvent (ethanol) 
with a final concentration of 1 mg/ml. 
 
 
   
 
Preparation of standard stock solution: 
The standard stock solution was prepared by dissolving the Ascorbic acid in suitable solvent 
(ethanol) with a final concentration of 1 mg/ml. 
Procedure: 
The effect of compound on DPPH radical was assayed using this method. Sample stock solutions 
(1.0 mg/ml) were diluted to appropriate final concentrations in ethanol. An ethanolic solution of 
1 ml of DPPH (0.3 mM) was added to 0.5 ml of the compound and allowed to react at room 
temperature in a dark place for 30 minutes. After 30 minutes the absorbance values were 
measured at 518 nm. All the measurements were taken as a triplicate values. From the average of 
the absorbance values, lower absorbance of the reaction mixture indicates higher free radical 
scavenging activity. The DPPH radical scavenging capability was calculated using the following 
equation: 
% inhibition = (ABS control – ABS test) /ABS control × 100 
              Where, 
                           ABS Control =Absorbance of ethanol+DPPH 
                         ABS Test     =Absorbance of DPPH + Compound /Standard 
The percentage antioxidant activity (% inhibition) was extrapolated against concentration of the 
compound and EC50 was determined graphically [154]. The results are tabulated in Table15 and 
Figure 19. 
6.3.2. FRAP RADICAL SCAVENGING METHOD 
 
FRAP (Ferric Reducing Ability of Plasma) is one of the most rapid test and very useful for 
routine analysis. The antioxidative activity is estimated by measuring the increase in absorbance 
caused by the formation of ferrous ions from FRAP reagent containing TPTZ (2, 4, 6 – tri (2 – 
pyridyl) – s – triazine) and FeCl36H2O. 
Principle 
The Ferric Reducing/Antioxidant Power assay measures the ability of antioxidants to reduce the 
complex of Fe(III)- 2,3,5-triphenyl-1,3,4-triaza-2-azoniacyclopenta- 1,4-diene chloride (TPTZ) 
to intense blue Fe(II) TPTZ complex at optimum pH (3.6). The reduction is quantitated by 
change in absorption at 593 nm. 
   
 
Reagents used 
Radical : FRAP 
Solvent   : Ethanol 
Standard: Ferrous sulphate 
Preparation of FRAP reagent 
FRAP reagent was prepared by mixing10 parts of 300 mM sodium acetate buffer at pH 3.6, 1 
part of 10.0 mM TPTZ solution and 1 part of 20.0 mM FeCl3. 6H2O solution.  
Preparation of test solution 
10 mg of each of the drug samples were accurately weighed separately and dissolved in 1ml of 
ethanol. These solutions were serially diluted with ethanol to obtain the lower dilutions. 
Procedure 
FRAP assay was carried out 0.2 ml of the compound is added to 3.8 ml of FRAP reagent and the 
reaction mixture was incubated at 37°C for 30 min and the increase in absorbance at 593 nm is 
measured. FeSO4 is used for calibration. The antioxidant capacity based on the ability to reduce 
ferric ions of sample is calculated from the linear calibration curve and expressed as Mmol 
FeSO4 equivalents per gram of sample [155]. The results are tabulated in Table16 and Figure 20. 
Percentage inhibition= [1− (absorbance of test/absorbance of control)] × 100 
 
6.3.3. ABTS RADICAL SCAVENGING METHOD 
 
The ABTS assay is based on the inhibition of the absorbance of radical cation, ABTS+, which 
has a characteristic wavelength at 745 nm, by antioxidants. In this assay, the ABTS radical which 
is a blue green chromogen, is generated in a stable form using potassium persulphate. The 
formed colored radical is then mixed with antioxidant in the reaction medium and the colored 
radical is converted back to colorless ABTS. Most often used chomogen compound is ABTS [2, 
2’azino-bis (3-ethyl benzthiazoline-6-sulphonic acid)]. 
Principle 
A ferryl myoglobin radical is formed from metmyoglobin and hydrogen peroxide. The ferryl 
myoglobin radical can oxidize ABTS (2, 2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) to 
generate a radical cation, ABTS-+, that is green in color.  Antioxidants supress this reaction by 
   
 
electron donation radical scavenging and inhibit the formation of the colored ABTS radical. 
Antioxidants inhibit the oxidation of ABTS by electron transfer radical scavenging. 
metmyoglobin + H2O2                     - ferryl myoglobin + H2O 
ABTS + - ferryl myoglobin                        ABTS-+   + metmyoglobin 
 
Reagents used 
Radical          :  ABTS 
Solvent          :  Ethanol 
Standard       :  Ascorbic acid 
Preparation of ABTS solution 
ABTS was dissolved in de-ionized water to 7 mM concentration, and potassium persulphate 
added to a concentration of 2.45 Mm. The reaction mixture was left to stand at room temperature 
overnight in dark before use. 
Preparation of test solution 
10 mg of each of the drug samples were accurately weighed separately and dissolved in 1 ml of 
ethanol. These solutions were serially diluted with ethanol to obtain the lower dilutions. 
Preparation of standard solution 
The standard stock solution was prepared by dissolving the Ascorbic acid in suitable solvent (1 
ml of ethanol) and serially diluted with ethanol to obtain the lower dilutions. 
Procedure 
The ABTS + assay was carried out using the improved assay of  1 ml of distilled ethanol was 
added to 0.2 ml of various concentrations of the drug samples or standard, and 0.16 ml of ABTS 
solution was added to make a final volume of 1.36 ml. Absorbance was measured 
spectrophotometrically, after 20 min at 745 nm. Blank was maintained without ABTS. The assay 
was performed at least in triplicates.IC50 value obtained is the concentration of the sample 
required to inhibit 50 % ABTS radical mono cation. The percentage of inhibition was measured 
by the following formula: 
% inhibition = (ABS control – ABS test) /ABS control × 100                        
      
 
   
 
 Where, 
                         ABS Control =Absorbance of ethanol+ABTS 
                         ABS Test     =Absorbance of ABTS + Compound /Standard 
The percentage antioxidant activity (% inhibition) was extrapolated against concentration of the 
compound and EC50 was determined graphically [156]. The results are tabulated in Table 17 and 
Figure 21. 
 
 
 
ANTIOXIDANT STUDIES 
Table 15. DPPH radical scavenging activity of synthesized compounds 
 
Compound code Concentration (μg /ml) % Inhibition EC50 Value 
Standard 
(Ascorbic acid) 
25 48.41 28 
50 71.82 
75 81.97 
100 91.07 
BTZP3a 25 11.39 87 
50 24.21 
75 39.56 
100 70.67 
BTZP3b 25 23.75 66 
50 37.76 
75 59.92 
100 74.76 
BTZP3c 25 14.16 75 
50 32.51 
75 50.18 
100 90.25 
BTZP3d 25 11.93 96 
50 28.42 
75 38.72 
100 55.07 
BTZP3e 25 36.50 47 
50 51.44 
75 63.07 
100 85.99 
BTZP3f 25 31.97  53 
50 48.42 
75 65.08 
100 91.09 
   
 
BTZP3g 
 
25 41.72 32 
50 69.37 
75 87.75 
100 91.19 
BTZP3h 25 35.04 44 
50 56.74 
75 76.13 
100 95.03 
BTZP3i 25 29.75 56 
50 46.19 
75 61.97 
100 90.83 
BTZP3j 25 15.71 66 
50 37.46 
75 56.98 
100 83.30 
BTZP3k 25 13.71 73 
50 24.91 
75 46.36 
100 89.93 
BTZP3l 25 12.55 82 
50 25.27 
75 43.63 
100 64.84 
 
 
       
Reagents used 
Reagents          :     DPPH 
Solvent            :      DMSO 
Standard          :      Ascorbic acid  
Absorbance     :      518nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Table 16. FRAP radical scavenging activity of synthesized compounds 
 
Compound code      Concentration (μg /ml) Absorption                  R2       
Standard 
(FeSO4.7H2O) 
25 1.0020 0.972 
50 1.1843 
75 1.2743 
100 1.3784 
BTZP3a 25 0.5506 0.961 
50 0.6780 
75 0.7896 
100 0.8342 
BTZP3b 25 0.5519 0.980 
50 0.5612 
75 0.5789 
100 0.5876 
BTZP3c 25 0.9612 0.989 
50 0.9636 
75 0.9658 
100 0.9673 
BTZP3d 25 0.1123 0.994 
50 0.1387 
75 0.1576 
100 0.1783 
BTZP3e 25 0.0023 0.998 
50 0.0046 
75 0.0065 
100 0.0087 
BTZP3f 25 0.6011 0.659 
50 0.6056 
75 0.6089 
100 0.7089 
BTZP3g 25 0.2022 0.992 
50 0.2045 
75 0.2061 
100 0.2087 
BTZP3h 25 0.0012 0.999 
50 0.0035 
75 0.0056 
100 0.0078 
BTZP3i 25 0.0020 0.980 
50 0.0037 
75 0.0049 
100 0.0058 
   
 
BTZP3j 25 0.3313 0.983 
50 0.3338 
75 0.3353 
100 0.3384 
BTZP3k 25 0.7432 0.978 
50 0.8990 
75 0.9848 
100 1.0775 
BTZP3l 25 0.0198 0.967 
50 0.0347 
75 0.0518 
100 0.0827 
 
 
 
 
Reagents used 
Reagents            :      FRAP  
Solvent               :      DMSO  
Standard            :      FeSO4.7H2O  
Absorbance        :      593nm 
 
 
 
 
Table 17. ABTS radical scavenging activity of synthesized compounds 
 
Compound code Concentration (μg /ml) % Inhibition EC50 Value 
Standard 
(Ascorbic acid) 
25 47.72 26 
50 59.43 
75 74.08 
100 82.31 
BTZP3a 25 38.73 70 
50 38.86 
75 46.35 
100 51.21 
BTZP3b 25 48.05 32 
50 59.71 
75 72.49 
100 81.65 
BTZP3c 25 39.35 54 
50 49.38 
75 56.99 
100 58.41 
   
 
BTZP3d 25 42.33 38 
50 54.55 
75 61.27 
100 71.30 
BTZP3e 25 14.45 81 
50 38.79 
75 49.70 
100 56.55 
BTZP3f 25 49.39 30 
50 62.67 
75 74.31 
100 87.98 
BTZP3g 25 26.09 59 
50 45.35 
75 62.79 
100 70.37 
BTZP3h 25 43.16 37 
50 55.67 
75 63.76 
100 76.26 
BTZP3i 25 12.96 71 
50 38.87 
75 51.70 
100 57.23 
BTZP3j 25 14.43 85 
50 32.68 
75 46.15 
100 59.08 
BTZP3k 25 37.02 43 
50 56.60 
75 74.43 
100 87.77 
BTZP3l 25 49.19 34 
50 51.11 
75 58.13 
100 64.51 
 
 
 
 
Reagents used 
Reagents             :       ABTS 
Solvent               :       DMSO 
Standard             :       Ascorbic acid  
Absorbance        :       745nm 
  
 
 
 
 
 
             
          
 
               
 
Figure 19
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Figure 20
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Figure 21. ABTS radical scavenging activity of synthesized compounds 
 
             
 
             
 
             
 
 
 
   
 
 
 
 
6.4. IN VITRO CYTOTOXIC SCREENING 
 
Several approaches have been used in the past for the measurement of cell viability and growth. 
Though trypan blue staining is a simple way to evaluate cell membrane integrity (and thus 
assume cell proliferation or death), the method is not sensitive and cannot be adapted for high-
throughput screening. The uptake of radioactive substances, usually tritium-labeled thymidine, 
can be measured. This method is accurate but is also time-consuming and involves handling of 
radioactive substances. [157] 
6.4.1. MTT ASSAY 
Principle 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole), is 
reduced to purple formazan by mitochondrial succinate dehydrogenase in living cells. The MTT 
enters the cells and passes into the mitochondria where it is reduced to an insoluble, coloured 
(dark purple) formazan product. The insoluble purple formazan product is converted to a colored 
solution using a solubilization agent (usually either DMSO, an acidified ethanol solution, or a 
solution of the detergent sodium dodecyl sulfate in diluted hydrochloric acid). The absorbance of 
this colored solution is then quantified by measuring at a certain wavelength (usually between 
500 and 600 nm) by a spectrophotometer. Since reduction of MTT can only occur in 
metabolically active cells, this assay gives a direct measure of the viability of cells. 
Procedure 
The mouse embryonic fibroblasts cell line (NIH 3T3) was obtained from National Centre for 
Cell Science (NCCS), Pune. NIH 3T3 cell line was grown in Dulbeccos modified Eagles 
medium containing 10% fetal bovine serum (FBS).  
For screening experiment, the cells were seeded into 96-well plates in 100 µl of medium 
containing 5% FBS, at plating density of 10,000 cells/well and incubated at 370C, 5% CO2, 95% 
air and 100% relative humidity for 24 h prior to addition of samples. The samples were 
solubilized in Dimethylsulfoxide and diluted in serum free medium. After 24 h, 100 µl of the 
medium containing the samples at various concentration  ( eg:  0.01, 0.1, 1, 10, and 100 µM ) 
   
 
was added and incubated at 370C, 5% CO2, 95% air and 100% relative humidity for 48 h. 
Triplicate was maintained and the medium containing without extracts were served as control. 
After 48h, 15 µl of MTT (5mg/ml) in phosphate buffered saline (PBS) was added to each well 
and incubated at 370C for 4 h. The medium with MTT was then flicked off and the formed 
formazan crystals were solubilized in 100 µl of DMSO and then measured the absorbance at 570 
nm using micro plate reader. The % cell inhibition was determined using the following formula. 
% cell Inhibition = 100- Abs (sample)/Abs (control) x100 
Non linear regression graph was plotted between percentage cell inhibition and Log10 
concentration and IC50 was determined using graph pad prism software [158] .The results are 
tabulated in Table18, 19 and Figure 22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
IN VITRO CYTOTOXIC STUDIES 
Table 18. Absorbance of various concentrations of samples  
 
 
 
 
 
 
 
 
Compound 
code 
Conc(uM) 0.01 0.1 1 10 100 Cont 
 
BTZP3b 
ABS 0.141 0.142 0.133 0.114 0.002 0.145 
 0.15 0.141 0.135 0.118 0.008 0.143 
 0.144 0.146 0.139 0.113 0.005 0.147 
Avg 0.145 0.143 0.135 0.115 0.005 0.146 
 
BTZP3e 
ABS 0.148 0.14 0.136 0.12 0 0.145 
 0.142 0.139 0.141 0.126 0.002 0.148 
 0.144 0.133 0.138 0.127 0.004 0.147 
Avg 0.144 0.137 0.138 0.124 0.002 0.146 
 
BTZP3f 
ABS 0.145 0.144 0.138 0.135 0.04 0.145 
 0.142 0.145 0.141 0.136 0.038 0.148 
 0.148 0.143 0.14 0.131 0.033 0.147 
AVS 0.145 0.144 0.139 0.134 0.037 0.146 
 
BTZP3g 
ABS 0.64 0.618 0.238 0.036 0 0.661 
 0.649 0.616 0.245 0.031 0 0.635 
 0.622 0.6 0.231 0.036 0 0.594 
AVS 0.637 0.611 0.238 0.034 0 0.63 
 
BTZP3i 
ABS 0.145 0.142 0.141 0.133 0.102 0.145 
 0.148 0.146 0.144 0.136 0.11 0.148 
 0.146 0.146 0.14 0.138 0.09 0.147 
Avg 0.146 0.144 0.141 0.135 0.103 0.146 
 
BTZP3l 
ABS 0.31 0.22 0.045 0.035 0.003 0.285 
 0.308 0.225 0.057 0.034 0.004 0.286 
 0.319 0.215 0.059 0.028 0.004 0.273 
Avg 0.312 0.22 0.053 0.032 0.003 0.281 
   
 
Table 19. Percentage cell inhibition produced by synthesized compounds at varying 
concentrations 
  
Compound 
code 
Conc (µM) % Cell Inhibition IC50 (µM) 
BTZP3b 0.01 1.13 19.34 
0.1 2.5 
1 7.5 
10 21.59 
100 96.59 
BTZP3e 
0.01 1.36 19.6 
0.1 6.36 
1 5.68 
10 15.22 
100 98.68 
 BTZP3f  
0.01 1.13 48 
0.1 1.81 
1 4.77 
10 8.63 
100 74.77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 BTZP3g 
0.01 -1.11 22.78 
0.1 2.96 
1 62.22 
10 94.55 
100 100 
 BTZP3i 
0.01 0.22 >100 
0.1 1.36 
1 3.40 
10 7.5 
100 29.77 
 BTZP3l 
0.01 -11.01 17.6 
0.1 21.80 
1 80.92 
10 88.50 
100 96.69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 22.  Invitro cytotoxic screening by MTT assay 
BTZP3b 
 
 
 
 
 
 
 
BTZP3f 
 
 
 
 
 
 
 
-3 -2 -1 0 1 2 3
0
20
40
60
80
100
Log10 concentration (μM)
%
 G
ro
w
th
 In
hi
bi
tio
n
   
 
BTZP3f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3 -2 -1 0 1 2 3
0
20
40
60
80
100
Log10 concentration (μM)
%
 G
ro
w
th
 In
hi
bi
tio
n
   
 
Chapter 7 
 
 
       
 
 
 
 
    
 
           Results and 
               Discussion 
   
 
7. RESULTS AND DISCUSSION 
7.1. CHEMISTRY 
In the present work 12 different schiff bases were synthesised in 4 steps. 
Step: 1 
4-Nitro-1, 3-benzothiazol-2-amine (BTZ) has been synthesized by precooled mixture of 2-
nitroaniline, ammonium thiocyanate and glacial acetic acid with bromine were stirred. The 
resulting mixture was neutralized with aqueous ammonia solution to form BTZ. 
Step: 2 
Ethyl cyano[2-(4-Nitro-1,3-benzothiazol-2-yl)hyrazinylidene]acetate (BTZE)  was synthesized 
by diazotization of 4-Nitro-1,3-benzothiazol-2-amine (BTZ) with sodium nitrite in concentrated 
hydrochloric acid and the resulting diazonium salt  was coupling with ethylcyanoacetate in 
presence of sodium acetate using ethanol as solvent. 
Step: 3 
The 5-amino-4-[2-(4-nitro-1, 3-benzothiazol-2 yl) hydrazinylidene]-2, 4-dihydro-3H -pyrazol -3-
one (BTZP) was synthesized by cyclising ethyl cyano [2-(4-Nitro-1, 3-benzothiazol-2-yl) 
hyrazinylidene] acetate (BTZE) with hydrazine hydrate using ethanol as solvent. 
Step: 4  
The title compounds (Schiff base of 5-amino-4-[2-(4-nitro-1,3-benzothiazol-2 
yl)hydrazinylidene]-2,4-dihydro-3H -pyrazol -3-one)  were synthesized by refluxing 5-amino-4-
[2-(4-nitro-1,3-benzothiazol-2 yl)hydrazinylidene]-2,4-dihydro-3H -pyrazol -3-one (BTZP)  with 
12 different aromatic aldehydes  in presence of acetic acid using ethanol as solvent. The 
percentage yield of the synthesized were found to be in the range of 70- 95%. Purity of all the 
newly compounds were checked by melting point and TLC Analysis and the structures were 
confirmed by UV, IR, 1HNMR and MASS spectral data were given in Table : 2,3,4&5. 
MOLECULAR DOCKING STUDY 
Docking study was performed by using ligand structure preparation by using build module then 
preparation of ligand in 3D structure form and the preparation of protein by removing unwanted 
molecule for using molecular modelling calculation than generated a receptor grid, further 
legend was docked using Autodock. 
Docking studies of designed and synthesized compounds (BTZP3a-l) were carried out using 
Autodock module version 4.0.The pose score of synthesized compounds benzothiazole 
   
 
containing pyrazolone derivatives were calculated on one tubercular protein, Thymidylate 
Kinase (PBD ID is 1MRS). 
Docking calculation revealed that among all the investigated compounds a similar trend in 
binding mode was observed.Synthesized compounds BTZP3h, BTZP3k, BTZP3l was shown H- 
bond interaction with Arg160:HH111,Arg160:HH211.Tyr34:HN-1,Arg160:HH11-
1,gln41:HE221, Val8:HN-1, LYS13:H32-1 of active site of thymidylate kinase (1MRS) 
inhibitor. The molecular docking study was tabulated in Table: 1and Fig: 1. 
 
7.2. DETERMINATION OF PHYSICOCHEMICAL PROPERTIES OF SYNTHESIZED 
COMPOUNDS 
Melting point analysis  
Melting points of all the newly synthesised compounds were checked and uncorrected and the 
values were given in Table: 2&3. 
Thin layer chromatography analysis 
The reaction time for all the compounds were determined by running TLC and a single spot was 
obtained. Rf Values of all the newly synthesised compounds were checked and were tabulated in 
Table: 2&3.  
Solubility 
Solubility was checked for all the newly synthesised compounds and found that all the 
compounds were soluble in non polar solvents (Chloroform, Benzene) and were tabulated in 
Table: 2&3. 
Polarizability 
Polarizability of all the newly synthesised compounds was calculated by using marvin sketch 
software and the values were tabulated in Table: 2&3. 
Log P 
LogP Values of all the newly synthesised compounds were calculated by using marvin sketch 
software and were tabulated in Table: 2&3. 
 
 
 
 
   
 
7.3. CHARACTERIZATION 
Ultraviolet and visible spectroscopy 
The structures of intermediates and all the newly synthesised compounds were determined and 
showed absorbance between 400-700nm and were tabulated in Table: 4&5 and Fig: 2&3. 
Infrared spectral analysis 
The structures of intermediates, compound BTZ confirmed by the presence of characteristic 
peaks in the region 700 cm-1,1629.55 cm-1, 3132.79 cm-1, 1348.32 cm-1 and 2936 cm-1, 1502.28 
cm-1 and 745.35 cm-1 associated for –C-S-C-, -C=N, -NH2, N=O and Ar stretching respectively. 
The compound BTZE showed the  disappearance of the characteristic bands of the -NH2 
stretching and also shows the stretching for cyanide group, ester group in the region 2360.44 cm-
1, 1786.44 cm-1 an  respectively. The compound BTZP confirmed the presence of -C-N, -C=O, -
C=N, -NH stretching, by the peaks at 1401.03 cm-1, 1715.62 cm-1, 1618.95 cm-1, 3132.79 cm-1, 
reappearance of the characteristic bands of the -NH2 stretching in the region 3343.05 cm-1  
respectively and also showed the disappearance of the characteristic bands of the cyanide group 
and ester group. 
All the Schiff base derivative compounds showed the characteristic peaks in the region 3400-
3100 cm-1 for associated NH stretching, 3100-2850,1600-1500,840- 790 cm-1 for Ar 
stretching,700-600 cm-1 for C-S-C stretching, 1690-1640 cm-1 for C=N stretching,<1500 cm-1 for 
C-N stretching, 1550 cm-1 - 1500 cm-1 for NO2 group  and 1700-1590 cm-1for C=O stretching. 
Compound BTZP3b containing – N (CH3)2 group showed absorption bands at 1321 cm-1. 
Compound BTZP3c, BTZP3e containing C-O-C group showed absorption bands at 1070.3 cm-1, 
1081.62 cm-1. Compound BTZP3f containing NO2 group showed absorption bands at 1512.88 
cm-1, for the N=O stretching.  The peak at 830.20 cm-1, 821 cm-1, 837.19 cm-1 could be assigned 
to C-Cl stretching in the compound BTZP3d, BTZP3h, BTZP3l. Presence of hydroxyl group was 
confirmed by the appearance of broad peak at 3430-3161 cm-1 in the compound BTZP3e, 
BTZP3g, BTZP3i, BTZP3j. Compound BTZP3k containing C-F group showed absorption bands 
at 1416 cm-1 and were tabulated in Table: 4&5 and Fig: 4&5. 
 
Nuclear magnetic resonance spectral analysis 
The structures of the newly synthesized compounds (BTZP, BTZP3a-l) were confirmed by 1H-
NMR spectra. The 1H-NMR spectra of all the synthesized compounds showed the absence of the 
   
 
peaks for the –NH2 proton signal at δ 8.32 ppm. All the synthesized  compounds showed 
multiplets in the range δ 6.32-8.59 for the protons of aromatic ring and a singlet at δ 6.15, 3.57-
3.89, 7.4-8.64 which may be assigned to -NH-N proton,-NH proton of pyrazolone,-N=CH proton 
of Schiff base. The spectrum of BTZP3b, BTZP3c, revealed a singlet at δ 3.04, 3.35 which may 
be assigned to -N (CH3)2, OCH3 proton. The spectra of compound BTZP3g showed singlet at δ 
9.87 corresponding to OH group and were tabulated in Table: 4&5 and Fig: 6&7. 
 
Mass spectral analysis 
Electron impact mass spectral analysis was carried out on randomly selected compounds 
BTZP3b, BTZP3g and BTZP3k. Mass spectrums of the compounds were in full agreement with 
their molecular weights and were tabulated in Table: 4&5 and Fig:8. 
 
7.4. BIOLOGICAL EVALUATION 
 In vitro antibacterial screening and bactericidal 
All the newly synthesised compounds (BTZP3a-l), at 100µg/disc concentration level were 
investigated for preliminary antibacterial activity against twelve bacterial strains (six gram 
positive and six gram negative) by the disc diffusion method, to determine the zone of inhibition. 
The results were compared with the standard drug (Ciprofloxacin) at 5µg/disc concentration 
level. All the newly synthesized compounds (BTZP3a-l) were screened minimum inhibitory 
concentration at 100-1.56µg/ml against all twelve bacterial strains (six gram positive and six 
gram negative) by serial dilution method followed by to determine the synthesized compounds 
are bactericidal / bacteriostatic agent. All the synthesized compounds are bactericidal in nature. 
All the synthesised compounds (BTZP3a-l) were shown mild to moderate activity against all the 
screened microbacterial (gram positive) strains. Among the screened gram positive bacterial 
strains, all the synthesised compounds (BTZP3a-l) shown moderate activity against (gram 
positive bacteria) with the percentage of inhibition range from 73-86 % and the MIC range at 
6.25 µg/ml concentration level. On the other hand, all the synthesized compounds (BTZP3a-l)  
showed mild activity against all the tested gram positive bacterial strains with the percentage of 
inhibition range 60-66% and the MIC range at 25 µg/ml concentration level. 
 
   
 
All the synthesized compounds (BTZP3a-l)  shown more potent or equal activity aganist 
Rhodosporum ruberum, Salmonella paratypic and Klebsellia pneumonie with the zone of 
inhibition range 80-175% and the MIC value at 3.12µg/ml concentration level.  Among the 
synthesised compounds (BTZP3h & BTZP3j) shown moderate activity against Pseudomonas 
aruginosa, (gram negative bacteria) with the percentage of inhibition range at 85% and the MIC 
range at 12.5 µg/ml concentration level. On the other hand,  all the synthesized compounds 
shown mild activity against Escherichia coli, Viberio cholera (gram negative strains) with the 
percentage  of inhibition range 45- 62%  and the MIC range at 25 µg/ml concentration  level. 
The preliminary antibacterial activity of synthesized compounds result shows better activity 
against gram negative bacteria than gram positive bacteria.  
In vitro antifungal screening and fungicidal 
All the newly synthesised compounds (BTZP3a-l), at 100µg/disc concentration level were 
investigated for preliminary antifungal activity against six fungal strains by the disc diffusion 
method, to determine the zone of inhibition. The results were compared with the standard drug 
(Clotrimazole) at 5µg/disc concentration level. All the newly synthesised compounds (BTZP3a-
l) showed MIC at 25-3.12 µg/ml concentration against all the screened fungal strains by serial 
dilution method and followed by determine whether the synthesized compounds are fungicidal / 
fungiostatic agents. Almost all newly synthesized compounds are fungicidal in nature. 
All the synthesised compounds were shown moderate to significant activity against all the 
screened fungal strains. The compounds BTZP3g and BTZP3h showed more potent or equal 
activity against all the tested fungal strains at 100µg/disc concentration level compared with 
standard clotrimazole at 5µg/disc concentration level with the zone of inhibition range 90-127% 
percentage and the MIC value at 3.12 µg/ml concentration level.   
In vitro antimycobacterial screening 
All the newly synthesised compounds were investigated for In-vitro anti mycobacterial activity 
by performing the resazurin microplate assay method. In-vitro antimycobacterial screening of six 
randomly selected samples using REMA revealed that, the compounds BTZP3g and BTZP3j 
possess antimycobacterial activity at a concentration of 100µg/ml. The compounds BTZP3h, 
BTZP3i, BTZP3k, and BTZP3l possess antimycobacterial activity at a concentration of 10 µg/ml 
respectively. 
 
   
 
In vitro antioxidant screening 
All the newly synthesised compounds were investigated for in-vitro antioxidant activity by 
DPPH, FRAP and ABTS assay methods. The ascorbic acid was used as standard reference for 
DPPH and ABTS assay methods. The ferrous sulphate was used as standard reference for FRAP 
assay methods. In vitro antioxidant DPPH assay method result showed that the compounds 
BTZP3g, BTZP3h and BTZP3e, were appreciable DPPH radical scavenging activity with EC50 
values of 47, 32 and 44 µg/ml respectively. In vitro antioxidant ABTS  assay method result 
shown that the compounds BTZP3b, BTZP3d, BTZP3f, BTZP3h, BTZP3k, BTZP3l were 
appreciable ABTS radical scavenging activity with EC50 values of 32,38,30,37,43,34 µg/ml 
respectively. In FRAP assay method all the synthesized compounds showed appreciable FRAP 
radical scavenging activity compared with standard except the compound (BTZP3f). 
In vitro cytotoxic screening 
The in-vitro cytotoxic studies were performed on randomly selected compounds (BTZP3b, 
BTZP3e, BTZP3f, BTZP3g, BTZP3i and BTZP3l) using MTT assay against normal cell line. 
The percentage cell Inhibition were calculated by using formula, 100- Abs (sample)/Abs 
(control) x100. Non linear regression graph was plotted between percentage cell inhibition and 
Log10 concentration and IC50 was determined using graph pad prism software. In-vitro cytotoxic 
MTT assay method results indicated that, the compounds BTZP3f and BTZP3i show less 
cytotoxic activity against normal cell line with IC50 value of 48µM and >100 µM respectively. 
Other compounds (BTZP3b, BTZP3e, BTZP3g, and BTZP3l) show IC50 value of 19.34, 19.6, 
22.78, and 17.6 µM respectively. 
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8. SUMMARY AND CONCLUSION 
8.1. CHEMISTRY 
In the present work totally twelve 5-amino substituted -4-[2-(4-nitro-1, 3-benzothiazol-2 yl) 
hydrazinylidene]-2, 4-dihydro-3H -pyrazol -3-one (BTZP3a-l) compounds were synthesised. The 
compound 4-nitro-1, 3-benzothiazol-2-amine (BTZ) was synthesized from 2-nitroaniline, 
ammonium thiocyanate and glacial acetic acid with bromine. Ethyl cyano [2-(4-Nitro-1, 3-
benzothiazol-2-yl)hyrazinylidene]acetate (BTZE)  was prepared by coupling through diazonium 
salts of 4-nitro-1,3-benzothiazol-2-amine (BTZ) with ethylcyanoacetate.  BTZE which was 
cyclised with hydrazine hydrate and the resulting product (BTZP) was subjected to schiff base 
reaction with 12 different aldehydes.  The yield was found to be 70-95% in all the stage.  
 
The final compounds were found to be soluble in non polar solvents.  Thin layer chromatography 
was used to find out the reaction time to completion the reaction and purity of the synthesized 
compounds. Melting points were taken in open glass capillary tubes and were uncorrected. The 
UV and IR spectra of synthesized compounds appeared in the exhibited regions. The structures 
of intermediates, the compound BTZ confirmed by the presence of characteristic peaks in the 
region 3132.79 cm-1associated for -NH2 stretching respectively. BTZE showed the  
disappearance of the characteristic bands of the -NH2 stretching and also shows the stretching for 
cyanide group, ester group in the region 2360.44 cm-1, 1786.44 cm-1 an  respectively. The 
compound BTZP confirmed, the disappearance of the characteristic bands of the cyanide group 
and ester group and also showed the reappearance of the characteristic bands of the -NH2 
stretching in the region 3343.05 cm-1  respectively. 
 
Compound BTZP3b containing – N (CH3)2 group showed absorption bands at 1321 cm-1. 
Compound BTZP3c, BTZP3e containing C-O-C group showed absorption bands at 1070.3 cm-1, 
1081.62 cm-1. Compound BTZP3f containing NO2 group showed absorption bands at 1512.88 
cm-1, for the N=O stretching.  The peak at 830.20 cm-1, 821 cm-1, 837.19 cm-1 could be assigned 
to C-Cl stretching in the compound BTZP3d, BTZP3h, BTZP3l. Presence of hydroxyl group was 
confirmed by the appearance of broad peak at 3430-3161 cm-1 in the compound BTZP3e, 
BTZP3g, BTZP3i, BTZP3j. Compound BTZP3k containing C-F group showed absorption bands 
at 1416 cm-1.  
   
 
 
The structures of the newly synthesized compounds (BTZP, BTZP3a-l) were confirmed by 1H-
NMR spectra. The 1H-NMR spectra of all the synthesized compounds showed the absence of the 
peaks for the –NH2 proton signal at δ 8.32 ppm. All the synthesized  compounds showed 
multiplets in the range δ 6.32-8.59 for the protons of aromatic ring and a singlet at δ 6.15, 3.57-
3.89,7.4-8.64ppm which may be assigned to –NH-N proton,-NH proton of pyrazolone,-N=CH 
proton of Schiff base. The spectrum of BTZP3b, BTZP3c, revealed a singlet at δ 3.04, 3.35 ppm 
which may be assigned to -N (CH3)2, OCH3 proton. The spectra of compound BTZP3g showed 
singlet at δ 9.87 ppm corresponding to OH group. 
 
Mass spectrums of the synthesized compounds were in full agreement with their molecular 
weights and studies showed satisfactory results. 
 
MOLECULAR DOCKING STUDY 
Molecular docking study was performed on one tubercular protein Thymidylate Kinase 
(1MRS).Synthesized compounds (BTZP3h, BTZP3k, BTZP3l) were shown pose score -5.82,-
5.68,-5.65 on thymidylate kinase inhibitor.  
 
8.2. BIOLOGICAL EVALUATION 
In vitro antibacterial screening 
All the newly synthesized compounds were screened for their preliminary antibacterial activity 
against Micrococcus luteus, Staphylococcus aureus, Bacillus substils, Corney bacterium, 
Bacillus lintus, Staphylococcus albus (gram positive bacterial strains) Escherichia Coli, 
Pseudomonas aruginosa, Rhodosporum ruberum, Vibrio cholera, Salmonella paratyphii and 
Klbsellia pneumonia (gram negative bacterial strains)  at a concentration of 100µg/disc and the 
result compared with standard ciprofloxacin 5 µg/discs concentration level. 
All the newly synthesized compounds (BTZP3g and BTZP3h) showed moderate activity with the 
percentage of inhibition range at 86% against Bacillus Lintus (gram positive bacterial strains) 
when compared with standard drug ciprofloxacin (5µg/disc) with MIC range at 6.25µg/ml 
concentration level.  
                   
   
 
                                         BTZP3g                                                 BTZP3h 
 
        
All the newly synthesized compounds (BTZP3d) demonstrated more zone of inhibition with the 
percentage of inhibition range at 175% against Salmonella paratyphii (gram negative bacterial 
strains) when compared with standard drug ciprofloxacin (5µg/disc) with MIC range at 
3.12µg/ml concentration level. 
            BTZP3d 
 
In vitro antifungal screening 
All the newly synthesized compounds were screened for their preliminary antifungal activity 
against Candida albicans, Monococcus purpureus, Aspergillus niger, Trichophyton rubrum, 
Aspergillus fumigates, Aspergillus parasites at a concentration of 100µg/disc. 
All the newly synthesised compounds (BTZP3a and BTZP3d), demonstrated more zone of 
inhibition with the percentage of inhibition range at130% against Aspergillus fumigates, 
Aspergillus parasites (fungal strains) when compared with standard drug clotrimazole (5µg/disc) 
and the MIC range at 3.12 µg/ml concentration level.  
                                                                                   
                         BTZP3a                                                              BTZP3d 
                             
   
 
 In vitro antitubercular screening 
Synthesized compounds (six) screened, four compounds BTZP3h, BTZP3i, BTZP3k, and 
BTZP3l were found to possess potent invitro anti -mycobacterial activity at 10 µg/ml 
concentration level. 
               BTZP3h                                                               BTZP3i 
                                     
                          BTZP3k                                                                 BTZP3l 
                                      
In vitro antioxidant screening 
All the newly synthesised compounds were investigated for in-vitro antioxidant activity by 
DPPH, FRAP and ABTS assay methods. The ascorbic acid was used as standard reference for 
DPPH and ABTS assay methods. The ferrous sulphate was used as standard reference for FRAP 
assay methods. The compounds BTZP3g was found to possess DPPH radical scavenging 
antioxidant activity with an EC50 of 32µg/ml, BTZP3h was found to possess FRAP radical 
scavenging antioxidant activity with an R2 of 0.999 and BTZP3f was found to possess ABTS 
radical scavenging antioxidant activity with an EC50 of 30µg/ml.                              
                                                       
 
                                                      BTZP3g 
                                                               
 
 
   
 
                   BTZP3h                                                            BTZP3f 
                             
 
 In vitro cytotoxic screening      
Six synthesized compounds were screened for in vitro cytotoxic study by MTT Assay method, 
the compounds BTZP3b, BTZP3l, were found to possess potent invitro cytotoxic activity. 
                   BTZP3b                                                                BTZP3l 
                 
 
8.3. CONCLUSION 
The 2-aryl benzothiazole moieties are already known for different biological activities. In the 
present investigation an attempt has been made for the synthesis of some novel benzothiazole 
containing pyrazolone analogues combining with different substituted aldehydes by schiff base 
reaction to get a good antimicrobial, bactericidal, fungicidal, in vitro anti-tubercular, antioxidant 
and cytotoxic activity with high toxic effects. 
Biological screening results clearly indicated that the compounds of the scheme have shown 
good in vitro antimicrobial, anti-tubercular, antioxidant activity compared with the standard 
drugs and almost all the newly synthesized compounds are bactericidal and fungicidal in nature. 
Unfortunately, the overall results indicate that they were weekly active with a low selectivity 
index as indicate by the cytotoxic effect. Even though the synthesized compounds showed good 
antimicrobial activity with less safety index, due to compounds have high toxicity towards 
normal cell lines.  
   
 
 The result obtained, taking into account the significant activities of the examined compounds, it 
is believed that further optimization of these identified chemical leads can probably lead to the 
development of more active molecules. Future studies are proposed reduced toxicity and to 
establish their in vivo efficacy and receptor interaction, after making suitable structural 
modifications. 
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ABSTRACT 
 
This project was aimed for the synthesis of Schiff Bases of 5-amino-4-[2-(4-nitro-1, 3-
benzothiazol-2 yl) hydrazinylidene]-2, 4-dihydro-3H -pyrazol -3-one. All the synthesized 
compounds were purified and characterized on the basis of spectral data (IR, 1HNMR & Mass 
spectra). Molecular docking study was performed for synthesized compounds (BTZP3a-l) on one 
tubercular protein, thymidylate kinase (PDB ID: 1MRS) by using Autodock module version 
4.0.Among the synthesized compounds docked, the compounds BTZP3h, BTZP3k, BTZP3l on 
1MRS shown -5.82, -5.68, -5.65 pose score. The title compounds were screened for their 
preliminary anti-microbial activity against gram positive, gram negative strains and fungal 
strains by disc diffusion method for determining zone of inhibition and serial dilution method 
was followed to determine minimum inhibitory concentration (MIC),  followed by to determine 
minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC). The 
preliminary antibacterial activity of synthesized compounds result shows better activity against 
gram negative bacteria than gram positive bacteria. Almost all the newly synthesized compounds 
(BTZP3a-l) are bactericidal and fungicidal in nature. Anti-tubercular activity by Resazurin 
microplate assay method against mycobacterium tuberculosis H37Rv using rifampicin as standard 
at 1 µg/ml concentration level. The synthesized compounds BTZP3h, BTZP3i, BTZP3k, BTZP3l 
were shown significant activity against mycobacterium tuberculosis H37Rv at 10µg/ml. Anti-
oxidant activity by DPPH, FRAP, ABTS assay method. The synthesized compounds BTZP3g, 
BTZP3h, BTZP3f were shown significant antioxidant activity. Cytotoxic activities by MTT 
assay method, the synthesized compounds BTZP3b, BTZP3l were found to possess potent 
invitro cytotoxic activity. 
 
 
 
 
